

## Supplementary Material A: Study Methods


### Methods

#### Study Design

This study employed a retrospective matched-cohort design and data from four large integrated US private healthcare claims databases—the Truven Health Analytics' MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Databases (the 'MarketScan Database'), the IQVIA PharMetrics Plus Database (the 'PharMetrics Database'), the Optum Clinformatics Claims Database (the 'Optum Database') and the Humana Medical, Laboratory and Pharmacy Claims Database (the 'Humana Database'). Data from the four databases were pooled for analyses to increase the power of the study to evaluate study outcomes and to improve the generalizability of study results. A schematic depicting the design of the study follows:

dures performed/services rendered and quantity of services (professional-service claims only). Data available for each outpatient pharmacy claim include the drug (class) dispensed, dispensing date, quantity dispensed and number of days supplied. Medical and pharmacy claims also include amounts paid (i.e. reimbursed) by health plans and patients for services rendered by health care providers (MarketScan, PharMetrics, Humana), or standard costs (Optum). Selected demographic and eligibility information (including age, sex, geographic region of residence, dates of plan eligibility) is available for all health plan enrollees in the databases. All data can be arrayed to provide a detailed chronology of medical and pharmacy services used by each plan member over time.

From each data extract, an analytic file comprising all patients and variables required for planned analyses was created from information contained exclusively within the source material. Each of the analytic files was patient-level,



#### Data Source(s)

The four study databases each comprise medical (i.e. facility and professional service) and outpatient pharmacy claims from a large number of participating U.S. private health plans, and spanned the period from 1 March 2014 through 30 June 2017 herein. Together, these four geographically diverse databases capture health care claims information for > 45 million plan members annually, including enrollees, their spouses and their dependents. Elderly persons who have elected to enrol in an employer-sponsored commercial plan (with or without Medicare supplemental coverage) or a Medicare Advantage Plan—and thus receive their health care coverage through a private health plan—also are included in the data source population.

Data available from each facility and professional-service claim include dates and places of service, diagnoses, proce-

and included data on patient demographic and clinical characteristics, VTE encounters, anticoagulant therapy and outcomes of interest (e.g. bleeding events, bleeding-related costs); variable names were standardized across analytic files. Variables were created based on information from medical and pharmacy claims, as well as enrolment records, which were linked at the patient level via encrypted identifiers provided by the data vendors.

Once created, the four independent, identically structured analytic files were then integrated (i.e. set or stacked, but not linked in any way), with the end product being one master analytic file that was used for planned analyses. No manipulation of data fields, or linking/ appending of information to observations, was performed on the master file. Patient-level information from the four study databases was pooled in a single analytic file to increase the power to address study

objectives and to enhance the generalizability of study findings.

### Source and Study Populations

The source population included all patients aged  $\geq 18$  years who, between 1 September 2014 and 30 June 2017, had an encounter for the treatment of VTE. Evidence of VTE was ascertained based on encounters in the acute-care inpatient setting or ambulatory-care setting (e.g. emergency department, physician office) with ICD-9-CM/ICD-10-CM diagnosis codes for lower extremity DVT or PE. The earliest such encounter for each patient was designated the 'index encounter'. Outpatient encounters followed by inpatient encounters within 7 days were considered inpatient encounters, unless apixaban or warfarin was initiated between encounters, in which case they were classified as outpatient encounters.

From the source population, all patients who received outpatient treatment with apixaban or warfarin (plus PAC bridging therapy) following their index encounters, and who met all other inclusion criteria, were selected as candidates for matching and thus inclusion in the study population. Outpatient use of apixaban or warfarin from the date of the index encounter (service date, if outpatient VTE; discharge date, if inpatient VTE) through the 30-day period thereafter was ascertained based on National Drug Codes (NDCs) (**► Supplementary Material B, ► Appendix A**). The first treatment (i.e. apixaban or warfarin) received by each patient was designated as the 'index therapy'. Warfarin patients with an index VTE encounter requiring outpatient care only who did not have evidence of PAC use (i.e. bridging therapy) during the period  $\pm 14$  days from first receipt of warfarin were excluded. Among warfarin patients who had evidence of PAC use during this period, the sub-set who received it beyond the 14-day period following initiation of warfarin was also excluded. Other inclusion criteria (e.g.  $\geq 6$  months of enrolment prior to index encounter; no evidence of atrial fibrillation/flutter, prior VTE, history of bleeding, active malignancy) are set forth below.

### Inclusion Criteria

Patients who met all of the following criteria (#1–#4) were considered for matching and thus inclusion in the study population:

- (1) An acute-care inpatient encounter with a principal or secondary diagnosis of VTE, or an ambulatory-care encounter with any diagnosis of VTE from 1 September 2014 to 30 June 2017. VTE diagnosis codes were based in large part on those recommended in the FDA-sponsored mini-sentinel report on definitions previously employed in studies using administrative data sources (Tamariz 2011):
  - ICD-9 415.1x (pulmonary embolism and infarction) and ICD-10 I2692, I2699, T82817A, T82818A (pulmonary embolism and infarction), excluding:
  - ICD-9 415.12 (septic pulmonary embolism).
  - ICD-10 I2690 (septic pulmonary embolism without acute cor pulmonale).

- ICD-9 451.xx (phlebitis and thrombophlebitis) and ICD-10 I801\*, I802\*, I803, I809 (phlebitis and thrombophlebitis), excluding:
- ICD-9 451.0 (of superficial vessels of lower extremities), 451.82 (of superficial veins of upper extremities) and 451.89 (other [axillary vein, jugular vein, subclavian vein, thrombophlebitis of breast]).
- ICD-10 I800\* (of superficial vessels of unspecified lower extremity), I808 (phlebitis and thrombophlebitis of other sites).
- ICD-9 453.xx (other venous embolism and thrombosis) and ICD-10 I821, I82220, I82221, I8240\*, I8241\*, I8242\*, I8243\*, I824Y\*, I8244\*, I8249\*, I824Z\*, I8281\*, I8261\*, I8262\*, I8260\*, I82A1\*, I82B1\*, I82C1\*, I82210, I82290, I82890, I829\* (other venous embolism and thrombosis), excluding:
- ICD-9 453.0 (Budd–Chiari syndrome), 453.3 (of renal vein), 453.5 (chronic venous embolism and thrombosis of deep vessels of lower extremity) and 453.7 (chronic venous embolism and thrombosis of other specified vessels).
- ICD-10 I820 (Budd–Chiari syndrome), I823 (of renal vein), I8250\*, I8259\*, I8251\*, I8252\*, I8253\*, I825Y\*, I8254\*, I825Z\* (chronic venous embolism and thrombosis of deep vessels of lower extremity), I8271\*, I8272\*, I8270\*, I82A2\*, I82B2\*, I82C2\*, I82211, I82291, I82891 (chronic venous embolism and thrombosis of other specified vessels).

Qualifying outpatient encounters followed by qualifying inpatient encounters within 7 days were considered inpatient episodes (unless apixaban or warfarin was initiated between encounters, in which case such episodes would be classified as outpatient encounters).

- (2) An outpatient pharmacy claim for apixaban or warfarin during the 30-day period following the index encounter (i.e. date of service if outpatient, date of discharge if inpatient).
- (3) Continuous and comprehensive medical/drug coverage for  $\geq 6$  months preceding the index encounter (i.e. date of service if outpatient, date of admission if inpatient).
- (4) Age  $\geq 18$  years.

### Exclusion Criteria

Apixaban and warfarin patients who met any of the following criteria (#1–#7) were excluded from the source population:

- (1) Evidence of atrial fibrillation/flutter or chemotherapy/radiation therapy for malignancy (other than non-melanoma skin cancer) during 6-month period preceding first receipt of index therapy.
- (2) Evidence of VTE (VTE event) during 6-month period preceding index encounter.
- (3) Evidence of malignancy (other than non-melanoma skin cancer) during 90-day period preceding first receipt of index therapy.
- (4) Evidence of any OAC/parenteral anticoagulant (PAC) use during the 30-day period preceding the index encounter, or evidence of any OAC/PAC use during the 6-month

period preceding the index encounter (excluding the 30-day period immediately preceding the index encounter) unless it is determined that such therapy was administered prophylactically.<sup>a</sup>

- (5) Evidence of inferior vena cava (IVC) filter or pregnancy at any time during the study period.
- (6) Evidence of receipt of another OAC on the day of first receipt of the index therapy (or during the period between the index encounter and initiation of the index therapy).
- (7) History of major/clinically relevant non-major (CRNM) bleeding event during 6-month period preceding first receipt of index therapy.

In addition, warfarin patients with an index VTE encounter requiring outpatient care only who did not have evidence of PAC use during the period beginning 14 days before, and ending 14 days after, first receipt of warfarin were excluded from the study population. Among warfarin patients who had evidence of PAC use during this period, the sub-set who received it beyond the 14-day period following initiation of index therapy was excluded. PAC use was identified based on corresponding Healthcare Common Procedure Coding System (HCPCS) Level II Codes on medical claims and NDCs on pharmacy claims; for the latter, therapy-days supplied was used to tally duration of PAC use.

Diagnosis, procedure and drug codes that were used to identify exclusionary conditions (except for bleeding history) and pharmacotherapy are set forth in **►Supplementary Material B**, **►Appendix C** (PAC), **►Appendix D** (OAC) and **►Appendix E** (conditions/procedures). Codes that were used to define a history of major/CRNM bleeding event are set forth in Section “Endpoint(s)/Outcome(s) Assessment.”

### Matching Procedure

Apixaban patients were matched to warfarin patients based on age, care setting of index encounter (inpatient vs. ambulatory), VTE diagnosis (DVT only vs. PE [with or without DVT]), VTE aetiology (provoked vs. unprovoked) and study database (MarketScan, PharMetrics, Optum, Humana), as well as their estimated propensity score using a fixed 1:1 ratio (without replacement) and nearest-neighbour approach. Provoked VTE was defined as an event that was preceded (within 3 months) by hormone therapy, fracture/trauma involving lower extremities, pelvic/orthopaedic surgery or hospitalization for medical or surgical reasons (**►Supplementary Material B**, **►Appendix H**). Propensity scores for receipt of apixaban versus warfarin—the dependent variable—were estimated using multivariable logistic regression; independent variables included age, gender, comorbidity profile, history of fall(s), history of fracture/

trauma involving lower extremities, history of selected surgeries and outpatient pharmacotherapy.

### Definitions

#### Study Period

The study period spanned from 1 September 2014 to 30 June 2017.

#### Baseline Period

The baseline period for evaluating demographic and clinical characteristics of patients spanned the 6-month period preceding first receipt of index therapy.

#### Study Follow-Up Period

Study outcomes were assessed from the day after therapy initiation through the subsequent 6-month period, date of health plan disenrollment, date of death (in hospital), date of index therapy discontinuation,<sup>b</sup> date of switch to another OAC, date of initiation of (new) PAC treatment<sup>c</sup> or end of study database (30 June 2017), whichever occurred first.

#### Endpoint(s)/Outcomes(s) Assessment

**Major Bleeding.** A major bleeding event was defined as an acute-care inpatient admission with:

- A principal or first-listed diagnosis code for:
  - Gastrointestinal (GI) bleeding.
  - Intracranial haemorrhage (ICH).
  - Other selected types/sites of bleeding (as defined below)

OR

- A procedure code for the treatment of bleeding (as defined below).

**CRNM Bleeding.** A CRNM bleeding event was defined as:

- An acute-care inpatient admission with a secondary diagnosis code for GI bleeding or other non-critical-care types/sites of bleeding (without a principal/first-listed diagnosis code for GI/ICH/other bleeding, or a procedure code for bleeding treatment); or
- An ambulatory-care encounter with a diagnosis code for GI bleeding or other non-critical-care types/sites of bleeding.

**Recurrent VTE.** A recurrent VTE event was defined as an acute-care inpatient admission with a corresponding principal/first-listed diagnosis as set forth in Section “Inclusion Criteria.” Encounters occurring within 7 days of the qualifying VTE event (i.e. index encounter) were not considered in identifying new (i.e. recurrent) events.

<sup>a</sup> Prophylactic use of OAC/PAC was determined based on the duration of use and timing of use (e.g., relative to knee/hip replacement surgery or medical inpatient admission); the operational algorithm that was employed to differentiate between prophylactic use and therapeutic use of OAC/PAC is set forth in Appendix B.

<sup>b</sup> Discontinuation of index therapy was defined as a gap of 30 days without available drug (based on days supplied from filled prescriptions).

<sup>c</sup> Episodes of PAC treatment were differentiated based on a gap in therapy  $\geq 2$  days that occurred after initiation of index therapy + 14 days.

**Table.** Codes for identification of bleeding events

Bleeding Category	ICD-9-CM Diagnosis Codes	ICD-10-CM Diagnosis Codes	ICD-9-CM Procedure Codes	ICD-10-CM Procedure Codes
<b>Major Bleeding</b>				
Gastrointestinal (GI)	456.0, 456.20, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 531.8x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 537.83, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.85, 578.x	K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K661, K625, K920, K921, K922, I8501, I8511, K2901, K2931, K2941, K2951, K2961, K2921, K2971, K2991, K2981, K5711, K5713, K5731, K5791, K5733, K5793, K5521, K31811	44.43	0W3PRZZ
Intracranial (ICH)	430.xx, 431.xx, 432.0x, 432.1x, 432.9x, 852.0x, 852.2x, 852.4x, 853.0x	I602, I604, I606, I607, I608, I609, I61*, I621, I629, I600*, I601*, I603*, I605*, I620*, S066X0A, S066X1A, S066X2A, S066X3A, S066X4A, S066X5A, S066X6A, S066X7A, S066X8A, S066X9A, S066X0A, S065X1A, S065X2A, S065X3A, S065X4A, S065X5A, S065X6A, S065X7A, S065X8A, S065X9A, S064X0A, S064X1A, S064X2A, S064X3A, S064X4A, S064X5A, S064X6A, S064X7A, S064X8A, S064X9A, S06360A, S06360A, S06350A, S06341A, S06342A, S06351A, S06352A, S06361A, S06362A, S06343A, S06344A, S06353A, S06354A, S06363A, S06364A, S06345A, S06355A, S06365A, S06346A, S06347A, S06348A, S06356A, S06357A, S06358A, S06366A, S06367A, S06368A, S06349A, S06359A, S06369A	---	---
Other	285.1, 360.43, 362.43, 362.81, 363.61, 363.62, 363.72, 364.41, 372.72, 374.81, 376.32, 377.42, 379.23, 423.0, 596.7x, 599.7x, 602.1x, 620.1, 621.4, 626.2, 626.5, 626.7, 626.8, 626.9, 719.1x, 782.7, 784.7, 784.8, 786.3x, 958.2, 997.02, 998.11	D62, I312, R31*, N421, N831, N857, N920, N923, N930, N897, N925, N938, N926, N939, R233, R04*, H356*, H210*, H113*, H0289, H431*, M2500, M2508, G973*, D780*, D782*, E360*, G975*, H952*, H954*, I9742, I9762, J956*, K916*, L760*, L762*, N996*, H4481*, H3573*, H3130*, H3131*, H3141*, H0523*, H4702*, M2501*, M2502*, M2503*, M2504*, M2505*, M2506*, M2507*, I9781*, I9782*, H591*, H5931*, H5932*, I9741*, I9761*, J9583*, K9184*, M9681*, M9683*, N9982*, T792XXA	99.04*	30230N1, 30230P1, 30233N1, 30233P1, 30240N1, 30240P1, 30243N1, 30243P1, 30250N1, 30250P1, 30253N1, 30253P1, 30260N1, 30260P1, 30263N1, 30263P1
<b>Clinically Relevant Non-Major Bleeding</b>				
Gastrointestinal (GI)	456.0, 456.20, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 537.83, 562.02, 562.03, 562.12, 562.13, 569.3, 569.85, 578.x	K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K625, K920, K921, K922, I8501, I8511, K2901, K2931, K2941, K2951, K2961, K2921, K2971, K2991, K2981, K5711, K5713, K5731, K5791, K5733, K5793, K5521, K31811	---	---
Intracranial (ICH)	---	---	---	---
Other	372.72, 374.81, 596.7x, 599.7x, 602.1x, 620.1, 621.4, 626.2, 626.5, 626.7, 626.8, 626.9, 782.7, 784.7, 784.8, 786.3x, 958.2	R31*, N421, N831, N857, N920, N923, N930, N897, N925, N938, N926, N939, R233, R04*, H113*, H0289, H952*, H954*, J956*, K916*, L760*, L762*, I9781*, I9782*, J9583*, K9184*, T792XXA	---	---

\*Hospitalizations with ICD-9-CM procedure code 99.04 and corresponding ICD-10-CM procedure codes will be classified as other bleeding events only in the absence of codes for GI or ICH bleeding events

**Other Study Variables**

Independent variables used in the estimation of propensity scores included demographic and clinical characteristics of patients that are believed to be associated with the study outcomes and/or choice of index therapy. It was anticipated that demographic characteristics would be available for nearly all study subjects. All other characteristics were defined based on the presence of specific data (e.g. diagnosis codes, procedure codes); the absence of such data was assumed to indicate the absence of the characteristic captured by the variable. All such characteristics were ascertained based on information available during the 6-month period preceding first receipt of index therapy.

Patient and treatment characteristics included: age; gender; geographic region of residence; type of insurance coverage; specialty of physician prescriber (if available); comorbidity profile (e.g. Deyo–Charlson Comorbidity Index [**►Supplementary Material B, ►Appendix F**]), and coagulopathy, ischaemic heart disease, peripheral vascular disease, heart failure, stroke or transient ischaemic attack [TIA], chronic obstructive pulmonary disease [COPD], liver disease, renal disease, thrombocytopenia, diabetes, anaemia, ulcer disease, dyspepsia, hypertension, thrombophilia, inflammatory bowel disease); recent history of falls, fracture/trauma involving the lower extremities, selected surgeries; and outpatient pharmacotherapy (e.g. recent history of statins, anti-platelet therapy, non-steroidal anti-inflammatory drug [NSAID], hormone therapy) (**►Supplementary Material B, ►Appendix G**).

Other characteristics that were examined during follow-up include dose of index therapy (i.e. with first and subsequent prescriptions), switching from index therapy to another oral anticoagulant, amount of index therapy received (i.e. days supplied), use of PAC (between index

encounter and initiation of index therapy, and subsequently) and duration of follow-up. These variables were not considered in the estimation of propensity scores.

**Data Analysis**

**Base Case Analysis**

The adequacy of the matching procedure in terms of patients' baseline characteristics was evaluated using standardized differences; a value < 0.1 was assumed to indicate a negligible difference in the characteristic between apixaban patients and warfarin patients (Austin 2011, Norman 2001).

Major bleeding, CRNM bleeding and recurrent VTE were compared between patients who received apixaban versus warfarin using shared frailty models (an extension of the Cox proportional hazards model that adjusts for correlation from matching). Kaplan–Meier curves were generated to depict the cumulative incidence of major bleeding, CRNM bleeding and recurrent VTE, respectively, and statistical comparisons were based on the stratified log-rank test (Klein 1997). The proportional hazards assumption was evaluated using published methods (Allison 2010, Pencina 2008). All analyses were performed in SAS 9.4 (SAS Institute, Cary, North Carolina, United States).

**Sub-Group and Sensitivity Analyses**

**Sub-Group Analyses.** Analyses of study measures, as described above, were repeated focusing alternatively on each data source—MarketScan Database, PharMetrics Database, Optum Database and Humana Database, respectively. **Sensitivity Analyses.** Use of a cohort design (i.e. without matching) was also employed. In these analyses, all patients who received outpatient treatment with apixaban or

warfarin (plus PAC bridging therapy) following their index encounters, and who met all other inclusion criteria were included in the study population. Bleeding events and recurrent VTE events were compared between patients who received apixaban versus warfarin using a shared frailty model (an extension of the Cox proportional hazards model that adjusts for intra-cluster [i.e. intra-database] correlation), with adjustment of estimated hazard ratios for systematic differences between treatment groups in baseline demographic and clinical characteristics. Patient characteristics were selected for inclusion in the multivariate model using a stepwise selection method (variable entry/retention criterion,  $p$ -value < 0.10).

In addition, an alternative approach to model specification using inverse proportional treatment weighting (IPTW) was employed to examine the impact of average treatment effect. The probability of receiving apixaban at study baseline was regressed on baseline covariates including VTE diagnosis, VTE care setting and VTE aetiology, as well as demographic and comorbidity profiles. Predicted probabilities were then inverted for apixaban patients and 1 minus predicted probabilities were inverted for warfarin patients. These inverses were then normalized to account for unequal sample sizes between treatment arms and were used as weights in evaluations of study outcomes using Cox proportional hazards models.

#### Power/Sample Size

Estimation of statistical power was based on the following assumptions, which were in turn based on exploratory analyses of data from earlier releases of the MarketScan and PharMetrics Databases (including data through 30 September 2015) and findings from the AMPLIFY clinical trial (Agnelli 2013):

- There would be at least 8,000 patients who received apixaban as outpatient treatment for VTE and met all other study entry criteria;
- The matched number of patients who received warfarin as outpatient treatment for VTE and met all other study entry criteria would total 8,000;
- Patients who received warfarin as outpatient treatment of VTE would have a 1.9% risk of a major bleeding event during the 6-month follow-up period; and

- Patients who received apixaban as outpatient treatment of VTE would have a 0.8% risk of a major bleeding event during the 6-month follow-up period.

Based on these assumptions and using a test to detect a difference between two proportions (Fleiss 1981), we calculated that  $\beta$  for this evaluation would <20% (two-sided  $\alpha = 0.05$ ), and that the study would have >80% power to detect the assumed difference in risk of major bleeding events between patients who received apixaban versus those who received warfarin.

#### Bibliography

- 1 Agnelli G, Buller HR, Cohen A, et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369(09):799–808
- 2 Allison PD. *Survival Analysis Using SAS: A Practical Guide*. 2nd ed. North Carolina: SAS Institute Inc; 2010
- 3 Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivariate Behav Res* 2011;46(03):399–424
- 4 Edelsberg J, Hagiwara M, Taneja C, Oster G. Risk of venous thromboembolism among hospitalized medically ill patients. *Am J Health Syst Pharm* 2006;63(20, Suppl 6):S16–S22
- 5 Fleiss, *Statistical Methods for Rates and Proportions*. 2nd ed. New York: John Wiley & Sons; 1981
- 6 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guidelines and expert panel report. *Chest* 2016; 149(02):315–352
- 7 Klein JP, Moeschberger ML *Survival Analysis: Techniques for Censored and Truncated Data*. New York: Springer-Verlag; 1997
- 8 Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *J Clin Epidemiol* 2001;54(04):387–398
- 9 Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J. Economic consequences of venous thromboembolism following major orthopedic surgery. *Ann Pharmacother* 2004;38(03):377–382
- 10 Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Statist Med* 2008;27(02):157–172
- 11 U.S. Food and Drug Administration (FDA). Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: Venous thromboembolism report. Department of Health and Human Services; 2011. Contact number HHSF2232009100061

## Supplementary Material B

## Appendix A

**Table.** NDC codes for apixaban and warfarin sodium (partial list for warfarin)

Brand Name	Generic Name	NDC Code	Form	Strength	Route
Eliquis	Apixaban	54569-6513-00	TAB	2.5 mg	ORAL
		54569-6514-00	TAB	5 mg	ORAL
		00003-0894-21	TAB	5 mg	ORAL
		00003-0893-21	TAB	2.5 mg	ORAL
		00003-0894-31	TAB	5 mg	ORAL
		00003-0893-31	TAB	2.5 mg	ORAL
Coumadin	Warfarin sodium	00056-0173-01	TAB	7.5 mg	ORAL
		00056-0188-01	TAB	3 mg	ORAL
		00056-0173-70	TAB	7.5 mg	ORAL
		00056-0174-01	TAB	10 mg	ORAL
		00056-0174-70	TAB	10 mg	ORAL
		00056-0174-75	TAB	10 mg	ORAL
		00056-0172-01	TAB	5 mg	ORAL
		00056-0172-90	TAB	5 mg	ORAL
		00056-0172-75	TAB	5 mg	ORAL
		00056-0172-70	TAB	5 mg	ORAL
		00056-0170-01	TAB	2 mg	ORAL
		00056-0170-70	TAB	2 mg	ORAL
		00056-0170-75	TAB	2 mg	ORAL
		00056-0170-90	TAB	2 mg	ORAL
		00056-0169-01	TAB	1 mg	ORAL
		00056-0169-75	TAB	1 mg	ORAL
		00056-0169-70	TAB	1 mg	ORAL
		00056-0169-90	TAB	1 mg	ORAL
		00056-0176-01	TAB	2.5 mg	ORAL
		00056-0176-75	TAB	2.5 mg	ORAL
		00056-0176-90	TAB	2.5 mg	ORAL
		00056-0176-70	TAB	2.5 mg	ORAL
		00056-0168-70	TAB	4 mg	ORAL
		00056-0168-75	TAB	4 mg	ORAL
		00056-0168-01	TAB	4 mg	ORAL
		00056-0189-70	TAB	6 mg	ORAL
		00056-0189-75	TAB	6 mg	ORAL
		00056-0189-01	TAB	6 mg	ORAL
		00056-0188-70	TAB	3 mg	ORAL
00056-0188-75	TAB	3 mg	ORAL		
00056-0173-75	TAB	7.5 mg	ORAL		
Jantoven	Warfarin sodium	00832-1216-89	TAB	5 mg	ORAL
		00832-1211-00	TAB	1 mg	ORAL
		00832-1216-00	TAB	5 mg	ORAL
		00832-1216-10	TAB	5 mg	ORAL
		00832-1218-89	TAB	7.5 mg	ORAL
		00832-1218-01	TAB	7.5 mg	ORAL
		00832-1218-50	TAB	7.5 mg	ORAL
		00832-1218-00	TAB	7.5 mg	ORAL
		00832-1215-89	TAB	4 mg	ORAL
		00832-1215-01	TAB	4 mg	ORAL
		00832-1215-00	TAB	4 mg	ORAL
		00832-1215-10	TAB	4 mg	ORAL
		00832-1217-89	TAB	6 mg	ORAL
		00832-1217-01	TAB	6 mg	ORAL
		00832-1217-00	TAB	6 mg	ORAL
		00832-1217-10	TAB	6 mg	ORAL
		00832-1214-89	TAB	3 mg	ORAL
		00832-1214-01	TAB	3 mg	ORAL
		00832-1214-10	TAB	3 mg	ORAL

## Appendix B<sup>d</sup>

Operational algorithm for differentiating between prophylactic versus therapeutic use of OAC/PAC agents:

**Step 1:** Identifying anticoagulation treatment episodes based on OAC and PAC use during the period of interest; an episode was assumed to be terminated when a gap  $\geq 30$  days occurred.

**Step 2:** Each identified anticoagulation treatment episode was determined as prophylactic use if:

(1) Duration of episode was  $\leq 42$  days; and

(2) Initiation date of anticoagulation in the episode occurred within 2 days before or 7 days after knee/hip replacement surgery; or

Initiation date of anticoagulation in the episode occurred within 7 days after the admission date of a hospitalization associated with a 'medically ill' primary diagnosis (see below for corresponding codes) and with LOS  $\geq 3$  days.

**Step 3:** A patient will be excluded from the study if any of his/her 6-month pre-index anticoagulation treatment episodes is determined as non-prophylactic use.

Preliminary list of ICD-9-CM Codes used to define and identify "medically ill" patients			
General Category	ICD-9-CM	General Category	ICD-9-CM
Infectious diseases	001	Infectious diseases	117
Infectious diseases	002	Infectious diseases	118
Infectious diseases	003	Infectious diseases	120
Infectious diseases	004	Infectious diseases	121
Infectious diseases	005	Infectious diseases	122
Infectious diseases	006	Infectious diseases	123
Infectious diseases	007	Infectious diseases	124
Infectious diseases	008	Infectious diseases	125
Infectious diseases	009	Infectious diseases	126
Infectious diseases	010	Infectious diseases	127
Infectious diseases	011	Infectious diseases	128
Infectious diseases	011.5	Infectious diseases	129
Infectious diseases	012	Infectious diseases	130
Infectious diseases	013	Infectious diseases	131
Infectious diseases	014	Infectious diseases	132
Infectious diseases	015	Infectious diseases	133
Infectious diseases	016	Infectious diseases	134
Infectious diseases	017	Infectious diseases	135
Infectious diseases	018	Infectious diseases	136
Infectious diseases	020	Infectious diseases	137
Infectious diseases	021	Infectious diseases	138
Infectious diseases	022	Infectious diseases	139
Infectious diseases	023	Cancer	140
Infectious diseases	024	Cancer	141
Infectious diseases	025	Cancer	142
Infectious diseases	026	Cancer	143
Infectious diseases	027	Cancer	144
Infectious diseases	030	Cancer	145
Infectious diseases	031	Cancer	146
Infectious diseases	032	Cancer	147
Infectious diseases	033	Cancer	148
Infectious diseases	034	Cancer	149
Infectious diseases	035	Cancer	150
Infectious diseases	036	Cancer	151
Infectious diseases	037	Cancer	152
Sepsis	038	Cancer	153
Infectious diseases	039	Cancer	154
Infectious diseases	040	Cancer	155
Infectious diseases	041	Cancer	156
Infectious diseases	042	Cancer	157
Infectious diseases	045	Cancer	158
Infectious diseases	046	Cancer	159
Infectious diseases	047	Cancer	160
Infectious diseases	048	Cancer	161
Infectious diseases	049	Cancer	162
Infectious diseases	050	Cancer	163
Infectious diseases	051	Cancer	164
Infectious diseases	052	Cancer	165
Infectious diseases	053	Cancer	170
Infectious diseases	054	Cancer	171
Infectious diseases	055	Cancer	172
Infectious diseases	056	Cancer	174
Infectious diseases	057	Cancer	175
Infectious diseases	058	Cancer	176
Infectious diseases	059	Cancer	179
Infectious diseases	060	Cancer	180
Infectious diseases	061	Cancer	181
Infectious diseases	062	Cancer	182
Infectious diseases	063	Cancer	183
Infectious diseases	064	Cancer	184
Infectious diseases	065	Cancer	185
Infectious diseases	066	Cancer	186
Infectious diseases	070	Cancer	187
Infectious diseases	071	Cancer	188
Infectious diseases	072	Cancer	189
Infectious diseases	073	Cancer	190
Infectious diseases	074	Cancer	191
Infectious diseases	075	Cancer	192
Infectious diseases	076	Cancer	193
Infectious diseases	077	Cancer	194
Infectious diseases	078	Cancer	195
Infectious diseases	079	Cancer	196
Infectious diseases	080	Cancer	197
Infectious diseases	081	Cancer	198
Infectious diseases	082	Cancer	199
Infectious diseases	083	Cancer	200
Infectious diseases	084	Cancer	201
Infectious diseases	085	Cancer	202
Infectious diseases	086	Cancer	203
Infectious diseases	087	Cancer	204
Infectious diseases	088	Cancer	205
Infectious diseases	090	Cancer	206
Infectious diseases	091	Cancer	207
Infectious diseases	092	Cancer	208
Infectious diseases	093	Cancer	209
Infectious diseases	094	Neurologic disorders	342
Infectious diseases	095	Neurologic disorders	342.1
Infectious diseases	096	Neurologic disorders	342.8
Infectious diseases	097	Neurologic disorders	342.9
Infectious diseases	098	Neurologic disorders	344
Infectious diseases	099	Neurologic disorders	344.1
Infectious diseases	100	Neurologic disorders	344.3
Infectious diseases	101	Neurologic disorders	344.6
Infectious diseases	102	Neurologic disorders	344.8
Infectious diseases	103	Neurologic disorders	344.9
Infectious diseases	104	Cardiovascular conditions	428
Infectious diseases	110	Cardiovascular conditions	433
Infectious diseases	111	Cardiovascular conditions	434
Infectious diseases	112	Neurologic disorders	438.2
Infectious diseases	114	Neurologic disorders	438.4
Infectious diseases	115	Neurologic disorders	438.5
Infectious diseases	116	Neurologic disorders	438.5
Infectious diseases		Infectious diseases	117
Infectious diseases		Infectious diseases	118
Infectious diseases		Infectious diseases	120
Infectious diseases		Infectious diseases	121
Infectious diseases		Infectious diseases	122
Infectious diseases		Infectious diseases	123
Infectious diseases		Infectious diseases	124
Infectious diseases		Infectious diseases	125
Infectious diseases		Infectious diseases	126
Infectious diseases		Infectious diseases	127
Infectious diseases		Infectious diseases	128
Infectious diseases		Infectious diseases	129
Infectious diseases		Infectious diseases	130
Infectious diseases		Infectious diseases	131
Infectious diseases		Infectious diseases	132
Infectious diseases		Infectious diseases	133
Infectious diseases		Infectious diseases	134
Infectious diseases		Infectious diseases	135
Infectious diseases		Infectious diseases	136
Infectious diseases		Infectious diseases	137
Infectious diseases		Infectious diseases	138
Infectious diseases		Infectious diseases	139
Infectious diseases		Cancer	140
Infectious diseases		Cancer	141
Infectious diseases		Cancer	142
Infectious diseases		Cancer	143
Infectious diseases		Cancer	144
Infectious diseases		Cancer	145
Infectious diseases		Cancer	146
Infectious diseases		Cancer	147
Infectious diseases		Cancer	148
Infectious diseases		Cancer	149
Infectious diseases		Cancer	150
Infectious diseases		Cancer	151
Infectious diseases		Cancer	152
Infectious diseases		Cancer	153
Infectious diseases		Cancer	154
Infectious diseases		Cancer	155
Infectious diseases		Cancer	156
Infectious diseases		Cancer	157
Infectious diseases		Cancer	158
Infectious diseases		Cancer	159
Infectious diseases		Cancer	160
Infectious diseases		Cancer	161
Infectious diseases		Cancer	162
Infectious diseases		Cancer	163
Infectious diseases		Cancer	164
Infectious diseases		Cancer	165
Infectious diseases		Cancer	170
Infectious diseases		Cancer	171
Infectious diseases		Cancer	172
Infectious diseases		Cancer	174
Infectious diseases		Cancer	175
Infectious diseases		Cancer	176
Infectious diseases		Cancer	179
Infectious diseases		Cancer	180
Infectious diseases		Cancer	181
Infectious diseases		Cancer	182
Infectious diseases		Cancer	183
Infectious diseases		Cancer	184
Infectious diseases		Cancer	185
Infectious diseases		Cancer	186
Infectious diseases		Cancer	187
Infectious diseases		Cancer	188
Infectious diseases		Cancer	189
Infectious diseases		Cancer	190
Infectious diseases		Cancer	191
Infectious diseases		Cancer	192
Infectious diseases		Cancer	193
Infectious diseases		Cancer	194
Infectious diseases		Cancer	195
Infectious diseases		Cancer	196
Infectious diseases		Cancer	197
Infectious diseases		Cancer	198
Infectious diseases		Cancer	199
Infectious diseases		Cancer	200
Infectious diseases		Cancer	201
Infectious diseases		Cancer	202
Infectious diseases		Cancer	203
Infectious diseases		Cancer	204
Infectious diseases		Cancer	205
Infectious diseases		Cancer	206
Infectious diseases		Cancer	207
Infectious diseases		Cancer	208
Infectious diseases		Cancer	209
Infectious diseases		Neurologic disorders	342
Infectious diseases		Neurologic disorders	342.1
Infectious diseases		Neurologic disorders	342.8
Infectious diseases		Neurologic disorders	342.9
Infectious diseases		Neurologic disorders	344
Infectious diseases		Neurologic disorders	344.1
Infectious diseases		Neurologic disorders	344.3
Infectious diseases		Neurologic disorders	344.6
Infectious diseases		Neurologic disorders	344.8
Infectious diseases		Neurologic disorders	344.9
Infectious diseases		Cardiovascular conditions	428
Infectious diseases		Cardiovascular conditions	433
Infectious diseases		Cardiovascular conditions	434
Infectious diseases		Neurologic disorders	438.2
Infectious diseases		Neurologic disorders	438.4
Infectious diseases		Neurologic disorders	438.5
Infectious diseases		Neurologic disorders	438.5
Infectious diseases		Other sepsis	038
Infectious diseases		Actinomycotic infections	039
Infectious diseases		Other bacterial infections	040
Infectious diseases		Bacterial infection in conditions classified elsewhere and of unspecified site	041
Infectious diseases		HIV	042
Infectious diseases		Acute poliomyelitis	045
Infectious diseases		Slow virus infection and prion diseases of central nervous system	046
Infectious diseases		Meningitis due to enterovirus	047
Infectious diseases		Other enterovirus diseases of central nervous system	048
Infectious diseases		Other non-arthropod-borne viral diseases of central nervous system	049
Infectious diseases		Smallpox	050
Infectious diseases		Coxsack and parvovirus	051
Infectious diseases		Chickengon	052
Infectious diseases		Herpes zoster	053
Infectious diseases		Herpes simplex	054
Infectious diseases		Measles	055
Infectious diseases		Rubella	056
Infectious diseases		Other viral exanthemata	057
Infectious diseases		Other human herpesvirus	058
Infectious diseases		Other poxvirus infections	059
Infectious diseases		Yellow fever	060
Infectious diseases		Dengue	061
Infectious diseases		Mosquito-borne viral encephalitis	062
Infectious diseases		Tick-borne viral encephalitis	063
Infectious diseases		Viral encephalitis transmitted by other and unspecified arthropods	064
Infectious diseases		Arthropod-borne hemorrhagic fever	065
Infectious diseases		Other arthropod-borne viral diseases	066
Infectious diseases		Viral hepatitis	070
Infectious diseases		Rabies	071
Infectious diseases		Mumps	072
Infectious diseases		Ornithosis	073
Infectious diseases		Specific diseases due to coxsackie virus	074
Infectious diseases		Infectious mononucleosis	075
Infectious diseases		Trachoma	076
Infectious diseases		Other diseases of conjunctiva due to viruses and chlamydiae	077
Infectious diseases		Other diseases due to viruses and chlamydiae unspecified site	078
Infectious diseases		Louse-borne (epidemic) typhus	080
Infectious diseases		Other typhus	081
Infectious diseases		Tick-borne rickettsiosis	082
Infectious diseases		Other rickettsiosis	083
Infectious diseases		Malaria	084
Infectious diseases		Leishmaniasis	085
Infectious diseases		Trypanosomiasis	086
Infectious diseases		Relapsing fever	087
Infectious diseases		Other arthropod-borne diseases	088
Infectious diseases		Congenital syphilis	090
Infectious diseases		Early syphilis symptomatic	091
Infectious diseases		Early syphilis latent	092
Infectious diseases		Cardiovascular syphilis	093
Infectious diseases		Neurosyphilis	094
Infectious diseases		Other forms of late syphilis with symptoms	095
Infectious diseases		Late syphilis, latent	096
Infectious diseases		Other and unspecified syphilis	097
Infectious diseases		Gonococcal infections	098
Infectious diseases		Other venereal diseases	099
Infectious diseases		Leptospirosis	100
Infectious diseases		Vincent's angina	101
Infectious diseases		Yaws	102
Infectious diseases		Pius	103
Infectious diseases		Other spirochetal infection	104
Infectious diseases		Dermatophytosis	110
Infectious diseases		Dermatomyiasis other and unspecified	111
Infectious diseases		Candidiasis	112
Infectious diseases		Coccidioidomycosis	114
Infectious diseases		Histoplasmosis	115
Infectious diseases		Blastomycotic infection	116
Infectious diseases		Other opportunistic mycoses	117
Infectious diseases		Opportunistic mycoses	118
Infectious diseases		Schistosomiasis (bilharziasis)	120
Infectious diseases		Other traumatic infections	121
Infectious diseases		Echinococcosis	122
Infectious diseases		Other cestode infection	123
Infectious diseases		Trichinosis	124
Infectious diseases		Filarial infection and dracunculiasis	125
Infectious diseases		Ascystosomiasis and necatoriasis	126
Infectious diseases		Other intestinal helminthiasis	127
Infectious diseases		Other and unspecified helminthiasis	128
Infectious diseases		Intestinal parasitism, unspecified	129
Infectious diseases		Toxoplasmosis	130
Infectious diseases		Trichomoniasis	131
Infectious diseases		Pediculosis and phthirus infestation	132
Infectious diseases		Acneosis	133
Infectious diseases		Other infestation	134

General Category	ICD-9-CM	Condition	General Category	ICD-9-CM	Condition
Infectious diseases	480	Viral pneumonia			
Infectious diseases	481	Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]			
Infectious diseases	482	Other bacterial pneumonia			
Infectious diseases	483	Pneumonia due to other specified organism			
Infectious diseases	484	Pneumonia in infectious diseases classified elsewhere			
Infectious diseases	485	Bronchopneumonia, organism unspecified			
Infectious diseases	486	Pneumonia, organism unspecified			
Infectious diseases	487	Influenza			
Respiratory conditions	490	Bronchitis, not specified as acute or chronic			
Respiratory conditions	491	Chronic bronchitis			
Respiratory conditions	492	Emphysema			
Respiratory conditions	493	Asthma			
Respiratory conditions	494	Bronchiectasis			
Respiratory conditions	495	Extrinsic allergic alveolitis			
Respiratory conditions	496	Chronic airway obstruction, not elsewhere classified			
Respiratory conditions	518.81	Acute respiratory failure			
Respiratory conditions	518.82	trauma and surgery			
Bowel diseases/obesity	555	Regional enteritis			
Bowel diseases/obesity	556	Ulcerative enterocolitis			
Infectious diseases	680	Carbuncle and furuncle			
Infectious diseases	681	Cellulitis and abscess of finger and toe			
Infectious diseases	682	Other cellulitis and abscess			
Infectious diseases	683	Acute lymphadenitis			
Infectious diseases	684	Impetigo			
Infectious diseases	685	Pilonidal cyst			
Infectious diseases	686	Other local infections of skin and subcutaneous tissue			
Rheumatic disorder	714.0	Rheumatoid arthritis			
Rheumatic disorder	715.15	Osteoarthritis, localized, primary, pelvic region and thigh			
Rheumatic disorder	715.16	Osteoarthritis, localized, primary, lower leg			
Rheumatic disorder	715.17	Osteoarthritis, localized, primary, ankle and foot			
Rheumatic disorder	715.25	Osteoarthritis, localized, secondary, pelvic region and thigh			
Rheumatic disorder	715.26	Osteoarthritis, localized, secondary, lower leg			
Rheumatic disorder	715.27	Osteoarthritis, localized, secondary, ankle and foot			
Rheumatic disorder	715.35	pelvic region and thigh			
Rheumatic disorder	715.36	lower leg			
Rheumatic disorder	715.37	ankle and foot			
Rheumatic disorder	724.2	Lumbago			
Rheumatic disorder	724.3	Sciatica			
Rheumatic disorder	733.13	Pathological fracture of vertebrae			
Infectious diseases	730	Osteomyelitis, periostitis and other infections involving bone			
Respiratory conditions	748.61	Congenital bronchiectasis			
Neurologic disorders	780.01	Coma			
Sepsis	790.7	Bacteremia			
Sepsis	995.91	Sepsis			
Sepsis	995.92	Severe sepsis			
Infectious diseases	996.6	graft			
Infectious diseases	997.62	Infection (chronic) of amputation stump			
Infectious diseases	998.3	Disruption of operation wound			
Infectious diseases	998.5	Postoperative infection not elsewhere classified			
Infectious diseases	999.3	Other infection due to medical care not elsewhere classified			

## Appendix C<sup>e</sup>

**Table.** HCPCS codes for parenteral anticoagulants

Drug	HCPCS Code
Low Molecular Weight Heparin	
Dalteparin	J1645
Enoxaparin	J1650
Tinzaparin	J1655
Heparin	J1642, J1644
Fondaparinux	J1652

<sup>e</sup> Codes from the NDC system were also be used to characterize use of PAC.



**Appendix D****Table.** NDC codes for other oral anticoagulants

Brand Name	Generic Name	NDC Code	Form	Strength	Route
Pradaxa	Dabigatran etexilate mesylate	00597-0107-54	CAP	75 mg	ORAL
		00597-0107-60	CAP	75 mg	ORAL
		00597-0108-60	CAP	110 mg	ORAL
		00597-0135-54	CAP	150 mg	ORAL
		00597-0135-60	CAP	150 mg	ORAL
		00597-0149-54	CAP	75 mg	ORAL
		00597-0149-60	CAP	75 mg	ORAL
		21695-0899-60	CAP	150 mg	ORAL
		54569-6276-00	CAP	150 mg	ORAL
Xarelto	Rivaroxaban	42254-0376-01	TAB	20 mg	ORAL
		50458-0578-10	TAB	15 mg	ORAL
		50458-0578-30	TAB	15 mg	ORAL
		50458-0578-90	TAB	15 mg	ORAL
		50458-0579-10	TAB	20 mg	ORAL
		50458-0579-30	TAB	20 mg	ORAL
		50458-0579-90	TAB	20 mg	ORAL
		50458-0580-10	TAB	10 mg	ORAL
		50458-0580-30	TAB	10 mg	ORAL
		50458-0584-51	TAB	15 mg; 20 mg	ORAL
Savaysa	Edoxaban	65597-0201-30	TAB	15 mg	ORAL
		65597-0202-05	TAB	30 mg	ORAL
		65597-0202-30	TAB	30 mg	ORAL
		65597-0202-90	TAB	30 mg	ORAL
		65597-0203-05	TAB	60 mg	ORAL
		65597-0203-30	TAB	60 mg	ORAL
		65597-0203-90	TAB	60 mg	ORAL

Appendix E<sup>f</sup>**Table.** Codes for exclusionary conditions and procedures

Condition/Procedure	Diagnosis Codes	Procedure Codes
Atrial Fibrillation/Flutter	427.31, 427.32	
Chemotherapy		See below
Radiation Therapy		77280, 77285, 77290, 77295, 77299, 77300, 77301, 77305, 77310, 77315, 77321, 77326, 77327, 77328, 77331, 77332, 77333, 77334, 77336, 77338, 77371, 77372, 77373, 77399, 77401, 77402, 77403, 77404, 77406, 77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77417, 77418, 77421, 77422, 77423, 77424, 77425, 77427, 77431, 77432, 77435, 77469, 77470, 77499, 77520, 77522, 77523, 77525, 77750, 77761, 77762, 77763, 77776, 77777, 77778, 77785, 77786, 77787, 77789, 77799, 92.20-92.29
Malignant Neoplasm (excluding non-melanoma skin)	140-209.3 (excluding 173)	
IVCF		ICD-9: 38.7x CPT: 37191, 37192, 37193, 37620
Pregnancy/Postpartum Care	630-679, V22, V23, V24, V27, V28, V61.6, V61.7, 792.3, 796.5	ICD-9: 72.00-75.99 CPT: 59000-59350, 59400-59430, 59510-59866, 59870-59899, 76801-76828, 83661-83664

<sup>f</sup> Corresponding ICD-10-CM codes are available upon request.

<b>Table. List of chemotherapy agents</b>	
<b>Chemotherapy Drug/Administration</b>	<b>HCPCS Level II Codes</b>
ALDESLEUKIN	J9015
ALEMTUZUMAB	C9110, S0087
ARSENIC TRIOXIDE	C9012
ASPARAGINASE	J9020
AZACITIDINE	C9218, J9025
BENDAMUSTINE	C9243, J9033
BEVACIZUMAB	J9035, C9214, C9257, Q2024, S0116
BLEOMYCIN	C9417, J9040
BORTEZOMIB	C9207
BRENTUXIMAB	C9287, J9042
BUSULFAN	C1178, J0594, J8510
CABAZITAXEL	C9276, J9043
CAPECITABINE	J8520, J8521
CARBOPLATIN	J9045
CARMUSTINE	C9437, J9050
CETUXIMAB	C9215, J9055
CHEMO -- unknown	J9999
CHLORAMBUCIL	S0172
CISPLATIN	C9418, J9060, J9062
CLADRIBINE	C9419, J9065
CLOFARABINE	C9129, J9027
CYCLOPHOSPHAMIDE	C9420, C9421, J8530, J9070, J9080, J9090, J9091, J9092, J9093, C1166, C9422, J9098, J9100, J9110
CYTARABINE	J9130, J9140, C9423
DACARBAZINE	J9120
DACTINOMYCIN	J9150, J951, C9424
DECITABINE	C9231, J0894
DENILEUKIN DIFTITOX	C1084, J9160
DOCETAXEL	J9170, J9171
DOXORUBICIN	C9415, J9000
DOXORUBICIN LIPOSOMAL	J9001, J9002, Q2048, Q2049, Q2050
EPIRUBICIN	J9178, C1167, J9180
ERIBULIN	J9179, C9280
ETOPOSIDE	J9181, J9182, C9414, C9425, J8560
EVEROLIMUS	J8561
FLOXURIDINE	J9200, C9426
FLUDARABINE	J9185, C9262, Q2025, J8562
FLUOROURACIL	J9190
GEFITINIB	J8565
GEMCITABINE	J9201
GEMTUZUMAB	C9004, J9300
HYDROXYUREA	S0176
IBRITUMOMAB	A9542
IBRUTINIB	J8999
IDARUBICIN	J9211, C9429
IDELALISIB	J8999
IFOSFAMIDE	J9208, C9427
IMATINIB	S0088
IPILIMUMAB	J9228, C9284
IRINOTECAN	J9206
IXABEPILONE	J9207, C9240
KADCYLA	C9131, J9354
LEUCOVORIN	J0640
LEVOLEUCOVORIN	J0641
LOMUSTINE	C9017, S0178
MECHLORETHAMINE	J9230
MELPHALAN	J9245, J8600

<b>Chemotherapy Drug/Administration</b>	<b>HCPCS Level II Codes</b>
MERCAPTOPURINE	S0108
METHOTREXATE	J9250, J9260, J8610
MITOMYCIN	J9280, J9290, J9291, C9432
MITOXANTRONE	J9293
NELARABINE	J9261
OFATUMUMAB	J9302
OXALIPLATIN	C9205, J9263
PACLITAXEL	C9127, C9431, J9264, J9265
PANITUMUMAB	C9235, J9303
PEGASPARGASE	J9266
PEMETREXED	C9213, J9305
PENTOSTATIN	J9268
PERTUZUMAB	C9292
PLICAMYCIN	J9270
PRALATREXATE	C9259, J9307
PROCARBAZINE	S0182
REGORAFENIB	J8999
RITUXIMAB	J9310
ROMIDEPSIN	C9265, J9325
STREPTOZOCIN	J9320
TEMOZOLOMIDE	C1086, C9253, J9328, J8700
TEMSIROLIMUS	C9239, J9330
TENIPOSIDE	Q2017
THIOTEPA	C9433, J9340
TOPOTECAN	J9350, J9351, J8705
TOSITUMOMAB	G3001
TRASTUZUMAB	J9355
TRETINOIN	S0117
VALRUBICIN	J9357
VINBLASTINE	J9360
VINCRIStINE	J9370, J9375, J9380
VINCRIStINE LIPOSOMAL	J9371
VINORELBINE	C9440, J9390
ZALTRAP	J9400

**Table.** List of chemotherapy administration codes

HCPCS Level I/II Codes	Description
36640	Arterial catheterization for prolonged infusion therapy (chemotherapy), cutdown
61517	Implantation of brain intracavitary chemotherapy agent (list separately in addit
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-ne
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neopla
96405	Chemotherapy administration; intralesional, up to and including 7 lesions
96406	Chemotherapy administration; intralesional, more than 7 lesions
96409	Chemotherapy administration; intravenous, push technique, single or initial subs
96411	Chemotherapy administration; intravenous, push technique, each additional substa
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, singl
96415	Chemotherapy administration, intravenous infusion technique; each additional hou
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolo
96417	Chemotherapy administration, intravenous infusion technique; each additional seq
96420	Chemotherapy administration, intra-arterial; push technique
96422	Chemotherapy administration, intra-arterial; infusion technique, up to one hour
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of p
96440	Chemotherapy administration into pleural cavity, requiring and including thorace
96445	Chemotherapy administration into peritoneal cavity, requiring and including peri
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or ca
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including
96542	Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reserv
96549	Unlisted chemotherapy procedure
99555	Home infuse, chemotherapy
Q0083	Chemotherapy administration by other than infusion technique only (eg subcutaneo
Q0084	Chemotherapy administration by infusion technique only, per visit
Q0085	Chemotherapy administration by both infusion technique and other technique(s) (e
S9329	Home infusion therapy, chemotherapy infusion; administrative services, professio
S9330	Home infusion therapy, continuous (twenty-four hours or more) chemotherapy infus
S9331	Home infusion therapy, intermittent (less than twenty-four hours) chemotherapy i

**Appendix F**<sup>9</sup> Deyo–Charlson Comorbidity Index

Diagnostic Category	ICD-9-CM codes	Points
Myocardial Infarction	410, 412	1
Congestive Heart Failure	428–428.9	1
Peripheral Vascular Disease	443.9, 441–441.9, 785.4, V43.4; 38.48 (Px)	1
Cerebrovascular Disease	430–438	1
Dementia	290–290.9	1
Rheumatologic Disease	710.1, 710.4, 714.0–714.2, 714.81, 725	1
Peptic Ulcer Disease	531–534.9	1
Mild Liver Disease	571.2, 571.5, 571.6, 571.4–571.49,	1
Diabetes	250–250.3, 250.7	1
Diabetes w/ Complications	250.4–250.6	2
Hemiplegia or Paraplegia	344.1, 342–342.9	2
Renal Disease	582–582.9, 583–583.7, 585, 586, 588–588.9	2
Any Malignancy	140–172.9, 174–195.8, 200–208.9	2
Moderate or Severe Liver Disease	572.2–572.8, 456.0–456.21	3
Metastatic Solid Tumour	196–199.1	6
AIDS	042–044.9	6

<sup>9</sup> Corresponding ICD-10-CM codes are available upon request.

Appendix G<sup>h</sup>

Table. Covariates -- variable types/definitions, operational algorithms, and codes

Covariate	Variable Type and Definition	Operational Algorithm
<b>Demographics</b>		
Age	Continuous: Categorical: 18-19, 50-64, 65-74, >=75	Based on year of index therapy initiation
Gender	Categorical: Male vs. female	
U.S. Geographical Region	Categorical: non-Hispanic white, non-Hispanic black, west, other	
Insurance Coverage	Categorical: comprehensive, HMO, PPO, POS, Other	
Physician Specialty	Categorical: based on empirical data	
<b>Comorbidity Profile</b>		
<b>Devo-Charlson Comorbidity Index</b>	Continuous	The Devo-Charlson Comorbidity Index will be based on information available during the pre-index period: 0 1 point: myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, cerebrovascular disease, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, diabetes (mild to moderate) 0 2 points: hemiplegia or paraplegia, renal disease, diabetes with complication, any malignancy (leukemia, lymphoma) 0 3 points: moderate or severe liver disease 0 6 points: malignant tumor, acquired immunodeficiency syndrome (AIDS) >=1 diagnosis during 6-month baseline period
<b>Acquired Immunodeficiency Syndrome (AIDS)</b>	Categorical: yes, no	042, V08 780 3, E880 0, E880 1 PX (ICD-9): 04.48, 04.53, 04.61-04.63, 04.07-04.69 PX (CPT): 98408, 98409, C0306, C0397, H0049, H0050 RX: alcohol abstinence
<b>Alcohol Abuse</b>	Categorical: yes, no	>=1 diagnosis, procedure, drug during 6-month baseline period
<b>Anemia</b>	Categorical: yes, no	>=1 diagnosis, procedure, drug during 6-month baseline period 280.1x-285.x
<b>Bleeding</b>	Categorical: yes, no	>=1 diagnosis during 6-month baseline period 853.0x Gastrointestinal bleeding: 455.2, 455.5, 455.8, 456.0x, 456.20, 530.7x, 530.82, 531.00, 531.01, 531.20, 531.21, 531.40, 531.41, 531.60, 531.61, 532.00, 532.01, 532.20, 532.21, 532.40, 532.41, 532.60, 532.61, 533.00, 533.01, 533.20, 533.21, 533.40, 533.41, 533.60, 533.61, 534.00, 534.01, 534.20, 534.21, 534.40, 534.41, 534.60, 534.61, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61, 537.83, 537.84, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3x or 569.85, 569.86, 578.0x, 578.1x, 578.9x Intracranial hemorrhage: 430.xx, 431.xx, 432.0x, 432.1x, 432.9x, 852.xx, 853.0x Other hemorrhage: 078.6x, 246.3x, 285.1, 286.5, 388.69, 360.43, 362.43, 362.81, 363.61, 363.62, 363.72, 364.41, 372.72, 374.81, 376.32, 377.42, 379.23, 423.0x, 459.0x, 593.81, 596.7x, 599.7x, 602.1x, 620.1x, 621.4x, 626.2x, 626.5x, 626.7x, 626.8x, 626.9x, 640.8x, 641.9x, 666.1x, 719.1x, 782.7x, 784.7x, 784.8x, 786.3x, 790.01, 948.2x, 997.02, 998.11
<b>Central Venous Catheter</b>	Categorical: yes, no	>=1 diagnosis, procedure during 6-month baseline period DX: 999.31, 999.32, 999.33 PX (ICD-9): 38.93, 38.95, 38.97, 89.62 PX (CPT): 36555-36569, S5520, S5522
<b>Cerebrovascular Disease (stroke and TIA)</b>	Categorical: yes, no	>=1 diagnosis, procedure during 6-month baseline period DX: 430, 431, 432.x, 433.xx, 434.xx, 435.x, 436, 437.0, 437.1, 437.8, 437.9, 438.xx, 997.02 PX (CPT): 35390, 37215, 37216 PX (ICD-9): 38.11, 38.12, 38.42 DX: 491.xx, 492.x, 496
<b>Chronic Obstructive Pulmonary Disease</b>	Categorical: yes, no	>=1 diagnosis during 6-month baseline period
<b>Coagulopathy</b>	Categorical: yes, no	>=1 diagnosis during 6-month baseline period DX: 286.6, 286.7, 286.9
<b>Congestive Heart Failure</b>	Categorical: yes, no	>=1 diagnosis during 6-month baseline period DX: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.xx PX (CPT): 33930, 33933, 33935, 33940, 33944, 33945, 33960, 33961, 33967, 33968, 33970, 33971, 33973, 33974, 33975, 33976, 33977, 33978, 33979, 33980, 33981, 33982, 33983, 33990, 33991, 33992, 33993 PX (ICD-9): 37.20, 37.26, 37.37, 37.51, 37.52, 37.53, 37.54, 37.55, 37.60, 37.61, 37.62, 37.63, 37.64, 37.65, 37.66, 37.67, 37.68

<sup>h</sup> Corresponding ICD-10-CM codes are available upon request.



Table. Covariates -- variable types/definitions, operational algorithms, and codes

Covariate	Variable Type and Definition	Operational Algorithm	Diagnosis/Procedure/Drug Codes
<b>Pharmacotherapy</b>			
ACE inhibitors/ARBs	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Antiarrhythmics	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Antiplatelets	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Aromatase inhibitors	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Beta blockers	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Calcium channel blockers	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Contraceptives (oral)	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Erythropoiesis stimulating agents	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Gastroprotective agents	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Hormones	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
NSAIDs	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
SERMs	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
Statins	Categorical: yes, no	>=1 drug during 6-month baseline period	RX: NDCs for corresponding drug/drug class
<b>Healthcare Utilization and Expenditures</b>			
Expenditures for any reason	Continuous	Measures of all-cause health care costs during the 6-month baseline period will be computed for: MD, ED, hospitalizations, and RX (outpatient)	
Expenditures for bleeding-related events	Continuous	Measures of bleeding-related health care costs during the 6-month baseline period will be computed for: MD, ED, hospitalizations	
Utilization for any reason	Continuous; Categorical: 0, 1-3, 4-5, >=6	Measures of all-cause HRU during the 6-month baseline period will be computed for: MD, ED, hospitalizations, and RX (outpatient)	
Utilization for bleeding-related events	Continuous; Categorical: 0, 1-3, 4-5, >=6	Measures of bleeding-related HRU during the 6-month baseline period will be computed for: MD, ED, hospitalizations, and RX (outpatient)	



Appendix H<sup>i</sup>**Table.** Factors identifying provoked VTE

Factors	Identifying Strategies
Hormone therapy	
Estrogen Therapy	ESTRADIOL CYPIONATE ESTRADIOL VALERATE ESTRADIOL ETHINYL ESTRADIOL ESTRADIOL BENZOATE ESTRADIOL ACETATE ESTRADIOL MICRONIZED ESTRONE ESTROGENS, CONJUGATED/MEPROBAM ESTROGENS, CONJUGATED ESTRIOL CHLOROTRIANISENE QUINESTROL DIENESTROL ESTROGENS,ESTERIFIED ESTROPIPATE ESTROGENS, CONJ., SYNTHETIC A ESTROGENS,CONJ., SYNTHETIC B ESTRIOL MICRONIZED
Combination E+P	ETHINYL ESTRADIOL/NORETH AC NORETHIND AC/ETHINYL ESTRADIOL ESTRADIOL/NORETH AC ESTRADIOL/NORGESTIMATE ESTRADIOL/LEVONORGESTREL ESTRADIOL/DROSPIRENONE ESTROGEN, CON/M-PROGEST ACET
Fracture/Trauma involving the Lower Extremities	ICD-9-CM: 820-828, 835-838, 890-897, 904, 928.0-928.3, 928.8, 928.9, 945, 956, 959.6, 959.7
Pelvic or orthopedic surgery	ICD-9-CM procedure code: 77.5-77.9, 78.5-78.9, 79.5-79.9, 80.5-80.9, 81
Any hospitalization	Any acute-care inpatient stay from medical claims

<sup>i</sup> Corresponding ICD-10-CM codes are available upon request

Online Supplement – Table 1. Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE

Inclusion/Exclusion Criteria Selection of Subjects	Humans (n [%])		Market Size (n [%])		Outpatient (n [%])		Pharmetrics (n [%])		Total		Total Population (n [%])	
	Apixaban	Warfarin	Apixaban	Warfarin	Apixaban	Warfarin	Apixaban	Warfarin	Apixaban	Warfarin	Apixaban	Warfarin
<b>Inclusion criteria:</b>												
Aged ≥18 years with diagnosis of VTE from September 1, 2014 to June 30, 2017.	22,647 (100.0%)	380,031 (100.0%)	---	---	---	---	---	---	463,551 (100.0%)	---	---	1,386,331 (100.0%)
Setting: Outpatient	68,128 (100.0%)	76,105 (100.0%)	---	---	---	---	---	---	114,633 (100.0%)	---	---	380,031 (100.0%)
Outpatient Care	136,527 (100.0%)	305,860 (100.0%)	---	---	---	---	---	---	348,868 (100.0%)	---	---	1,003,331 (72.4%)
<b>Diagnosis:</b>												
Diagnosis of PE (with or without DVT)	6,428 (10.0%)	110,426 (29.1%)	---	---	---	---	---	---	132,802 (18.6%)	---	---	406,084 (29.3%)
Diagnosis of DVT Only	155,233 (100.0%)	283,399 (73.9%)	---	---	---	---	---	---	330,499 (71.4%)	---	---	979,250 (70.7%)
Prevalence: Unprovoked	67,668 (10.5%)	94,834 (25.0%)	---	---	---	---	---	---	162,502 (17.6%)	---	---	347,036 (25.1%)
plus ≥1 outpatient pharmacy claim for apixaban or warfarin during 30-day period following the index encounter	10,934 (4.5%)	40,709 (18.4%)	11,245 (13.0%)	62,640 (16.5%)	10,987 (14.4%)	57,337 (17.9%)	15,975 (16.4%)	76,117 (16.6%)	92,090 (19.9%)	48,239 (13.5%)	236,603 (17.1%)	838,226 (60.5%)
Exclusion criteria:												
plus no claims for conditions/procedures:												
No claims for atrial fibrillation/flutter during 6-month period prior to index therapy	6,229 (2.8%)	23,253 (10.6%)	8,853 (4.4%)	48,547 (12.8%)	6,672 (2.1%)	33,915 (10.6%)	10,698 (2.3%)	54,109 (11.7%)	64,605 (13.9%)	32,301 (2.3%)	160,148 (11.6%)	192,272 (13.9%)
No claims for myocardial infarction during 6-month period prior to index therapy	4,900 (2.2%)	19,724 (8.9%)	7,224 (2.6%)	41,581 (11.0%)	5,673 (1.8%)	29,105 (9.1%)	9,245 (2.0%)	48,804 (10.3%)	9,088 (12.5%)	27,886 (2.0%)	138,499 (10.0%)	166,994 (12.1%)
No claims for malignancy during 90-day period prior to index therapy	4,852 (2.2%)	19,068 (8.6%)	7,357 (3.2%)	40,593 (10.7%)	5,533 (1.7%)	28,148 (8.8%)	9,034 (1.9%)	47,399 (10.2%)	56,433 (12.2%)	26,776 (1.9%)	135,118 (9.8%)	168,894 (12.2%)
No claims for PCI during study period	4,830 (2.2%)	23,700 (10.8%)	7,332 (3.2%)	39,707 (10.4%)	5,478 (1.7%)	27,755 (8.7%)	8,221 (1.8%)	41,674 (9.0%)	49,895 (10.8%)	25,761 (1.9%)	128,022 (9.2%)	153,789 (11.1%)
No claims for pregnancy during study period	4,837 (2.2%)	18,888 (8.5%)	6,975 (3.1%)	37,264 (9.8%)	5,328 (1.6%)	28,416 (8.3%)	7,931 (1.7%)	39,467 (8.5%)	47,388 (10.2%)	24,971 (1.8%)	121,468 (8.8%)	143,279 (10.4%)
plus no evidence of any OAC/PTC use during 30-day period prior to index encounter	4,614 (2.1%)	18,011 (8.1%)	6,566 (2.9%)	34,681 (9.1%)	5,285 (1.6%)	28,262 (8.2%)	7,830 (1.7%)	39,292 (8.5%)	47,162 (10.2%)	24,661 (1.8%)	120,884 (8.7%)	143,279 (10.4%)
plus no evidence of receipt of OAC during period between index encounter and index therapy initiation**	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus no claims for VTE during 6-month period prior to index encounter	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)	28,387 (8.2%)	7,830 (1.7%)	38,859 (8.2%)	46,679 (10.0%)	24,289 (1.8%)	119,739 (8.6%)	143,279 (10.4%)
plus evidence of PTC within +/- 14 days of warfarin initiation (ambulatory care only)	4,566 (2.1%)	17,000 (7.7%)	6,556 (2.9%)	33,131 (8.7%)	5,247 (1.6%)							

Online Supplement – Table 2. Characteristics of matched patients receiving apixaban or warfarin as outpatient therapy for VTE

Qualifying VTE Encounter, n (%)	Humana		Aetna		Munich		Aetna		Optum		Aetna		Pharmetrics		Total Population																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
	Apixaban (n=3,118)	Warfarin (n=3,118)	Apixaban (n=4,358)	Warfarin (n=4,358)	Apixaban (n=4,358)	Warfarin (n=4,358)	Apixaban (n=4,358)	Warfarin (n=4,358)	Apixaban (n=5,951)	Warfarin (n=5,951)	Apixaban (n=5,951)	Warfarin (n=5,951)	Apixaban (n=17,878)	Warfarin (n=17,878)	Apixaban (n=17,878)	Warfarin (n=17,878)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Setting:																	Acute-care inpatient	2,097 (63.2%)	2,097 (63.2%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,334 (55.0%)	2,334 (55.0%)	2,655 (44.5%)	2,655 (44.5%)	9,683 (54.2%)	9,683 (54.2%)	9,683 (54.2%)	9,683 (54.2%)	Ambulatory care	1,221 (38.6%)	1,221 (38.6%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,909 (45.0%)	1,909 (45.0%)	3,300 (55.5%)	3,300 (55.5%)	8,195 (45.8%)	8,195 (45.8%)	8,195 (45.8%)	8,195 (45.8%)	Diagnosis:																	PE (with or without DVT)	1,376 (41.5%)	1,376 (41.5%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	2,120 (50.1%)	2,120 (50.1%)	2,210 (37.1%)	2,210 (37.1%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)	PE with DVT	765 (23.9%)	765 (23.9%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,154 (26.5%)	1,154 (26.5%)	1,210 (20.7%)	1,210 (20.7%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)	PE without DVT	611 (19.1%)	611 (19.1%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	966 (22.5%)	966 (22.5%)	1,000 (16.4%)	1,000 (16.4%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)	DVT only	1,342 (42.3%)	1,342 (42.3%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	2,044 (47.0%)	2,044 (47.0%)	2,000 (33.8%)	2,000 (33.8%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)	Prevented atherothrombosis	798 (24.1%)	798 (24.1%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	892 (21.0%)	892 (21.0%)	1,369 (23.0%)	1,369 (23.0%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)	Prevented thromboembolism	2,520 (75.9%)	2,520 (75.9%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,551 (79.0%)	3,551 (79.0%)	4,592 (77.0%)	4,592 (77.0%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)	Age, n (%)																	Mean (SD)	71.5 (13.3)	71.5 (13.3)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	65.2 (15.5)	65.2 (15.5)	51.4 (12.1)	51.4 (12.1)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	Median	72	72	57	57	57	57	57	57	67	67	53	53	60	60	60	60	Age (years), n (%)																	18-49 years	186 (5.6%)	186 (5.6%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	732 (17.3%)	732 (17.3%)	2,389 (38.4%)	2,389 (38.4%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	50-64 years	663 (20.0%)	663 (20.0%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,169 (27.6%)	1,169 (27.6%)	3,140 (52.7%)	3,140 (52.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	65-74 years	1,162 (35.0%)	1,162 (35.0%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	1,059 (25.0%)	1,059 (25.0%)	411 (6.9%)	411 (6.9%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	≥75 years	1,307 (39.4%)	1,307 (39.4%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	1,283 (30.2%)	1,283 (30.2%)	121 (2.0%)	121 (2.0%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Sex, n (%)																	Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)	
Acute-care inpatient	2,097 (63.2%)	2,097 (63.2%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,597 (59.6%)	2,334 (55.0%)	2,334 (55.0%)	2,655 (44.5%)	2,655 (44.5%)	9,683 (54.2%)	9,683 (54.2%)	9,683 (54.2%)	9,683 (54.2%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Ambulatory care	1,221 (38.6%)	1,221 (38.6%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,759 (40.4%)	1,909 (45.0%)	1,909 (45.0%)	3,300 (55.5%)	3,300 (55.5%)	8,195 (45.8%)	8,195 (45.8%)	8,195 (45.8%)	8,195 (45.8%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Diagnosis:																	PE (with or without DVT)	1,376 (41.5%)	1,376 (41.5%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	2,120 (50.1%)	2,120 (50.1%)	2,210 (37.1%)	2,210 (37.1%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)	PE with DVT	765 (23.9%)	765 (23.9%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,154 (26.5%)	1,154 (26.5%)	1,210 (20.7%)	1,210 (20.7%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)	PE without DVT	611 (19.1%)	611 (19.1%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	966 (22.5%)	966 (22.5%)	1,000 (16.4%)	1,000 (16.4%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)	DVT only	1,342 (42.3%)	1,342 (42.3%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	2,044 (47.0%)	2,044 (47.0%)	2,000 (33.8%)	2,000 (33.8%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)	Prevented atherothrombosis	798 (24.1%)	798 (24.1%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	892 (21.0%)	892 (21.0%)	1,369 (23.0%)	1,369 (23.0%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)	Prevented thromboembolism	2,520 (75.9%)	2,520 (75.9%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,551 (79.0%)	3,551 (79.0%)	4,592 (77.0%)	4,592 (77.0%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)	Age, n (%)																	Mean (SD)	71.5 (13.3)	71.5 (13.3)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	65.2 (15.5)	65.2 (15.5)	51.4 (12.1)	51.4 (12.1)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	Median	72	72	57	57	57	57	57	57	67	67	53	53	60	60	60	60	Age (years), n (%)																	18-49 years	186 (5.6%)	186 (5.6%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	732 (17.3%)	732 (17.3%)	2,389 (38.4%)	2,389 (38.4%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	50-64 years	663 (20.0%)	663 (20.0%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,169 (27.6%)	1,169 (27.6%)	3,140 (52.7%)	3,140 (52.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	65-74 years	1,162 (35.0%)	1,162 (35.0%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	1,059 (25.0%)	1,059 (25.0%)	411 (6.9%)	411 (6.9%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	≥75 years	1,307 (39.4%)	1,307 (39.4%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	1,283 (30.2%)	1,283 (30.2%)	121 (2.0%)	121 (2.0%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Sex, n (%)																	Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																				
PE (with or without DVT)	1,376 (41.5%)	1,376 (41.5%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	1,954 (44.9%)	2,120 (50.1%)	2,120 (50.1%)	2,210 (37.1%)	2,210 (37.1%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)	7,322 (41.0%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
PE with DVT	765 (23.9%)	765 (23.9%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,054 (24.2%)	1,154 (26.5%)	1,154 (26.5%)	1,210 (20.7%)	1,210 (20.7%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)	4,165 (23.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
PE without DVT	611 (19.1%)	611 (19.1%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	900 (20.7%)	966 (22.5%)	966 (22.5%)	1,000 (16.4%)	1,000 (16.4%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)	3,157 (17.7%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
DVT only	1,342 (42.3%)	1,342 (42.3%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	1,944 (45.0%)	2,044 (47.0%)	2,044 (47.0%)	2,000 (33.8%)	2,000 (33.8%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)	7,015 (39.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Prevented atherothrombosis	798 (24.1%)	798 (24.1%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	1,010 (23.2%)	892 (21.0%)	892 (21.0%)	1,369 (23.0%)	1,369 (23.0%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)	4,969 (27.8%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Prevented thromboembolism	2,520 (75.9%)	2,520 (75.9%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,348 (76.8%)	3,551 (79.0%)	3,551 (79.0%)	4,592 (77.0%)	4,592 (77.0%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)	13,809 (77.2%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Age, n (%)																	Mean (SD)	71.5 (13.3)	71.5 (13.3)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	65.2 (15.5)	65.2 (15.5)	51.4 (12.1)	51.4 (12.1)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	Median	72	72	57	57	57	57	57	57	67	67	53	53	60	60	60	60	Age (years), n (%)																	18-49 years	186 (5.6%)	186 (5.6%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	732 (17.3%)	732 (17.3%)	2,389 (38.4%)	2,389 (38.4%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	50-64 years	663 (20.0%)	663 (20.0%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,169 (27.6%)	1,169 (27.6%)	3,140 (52.7%)	3,140 (52.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	65-74 years	1,162 (35.0%)	1,162 (35.0%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	1,059 (25.0%)	1,059 (25.0%)	411 (6.9%)	411 (6.9%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	≥75 years	1,307 (39.4%)	1,307 (39.4%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	1,283 (30.2%)	1,283 (30.2%)	121 (2.0%)	121 (2.0%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Sex, n (%)																	Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																											
Mean (SD)	71.5 (13.3)	71.5 (13.3)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	57.8 (15.8)	65.2 (15.5)	65.2 (15.5)	51.4 (12.1)	51.4 (12.1)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)	60.0 (16.0)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Median	72	72	57	57	57	57	57	57	67	67	53	53	60	60	60	60																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Age (years), n (%)																	18-49 years	186 (5.6%)	186 (5.6%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	732 (17.3%)	732 (17.3%)	2,389 (38.4%)	2,389 (38.4%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	50-64 years	663 (20.0%)	663 (20.0%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,169 (27.6%)	1,169 (27.6%)	3,140 (52.7%)	3,140 (52.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	65-74 years	1,162 (35.0%)	1,162 (35.0%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	1,059 (25.0%)	1,059 (25.0%)	411 (6.9%)	411 (6.9%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	≥75 years	1,307 (39.4%)	1,307 (39.4%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	1,283 (30.2%)	1,283 (30.2%)	121 (2.0%)	121 (2.0%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Sex, n (%)																	Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																														
18-49 years	186 (5.6%)	186 (5.6%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	1,221 (28.1%)	732 (17.3%)	732 (17.3%)	2,389 (38.4%)	2,389 (38.4%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)	4,428 (24.8%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
50-64 years	663 (20.0%)	663 (20.0%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,902 (43.7%)	1,169 (27.6%)	1,169 (27.6%)	3,140 (52.7%)	3,140 (52.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)	6,874 (38.7%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
65-74 years	1,162 (35.0%)	1,162 (35.0%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	510 (11.7%)	1,059 (25.0%)	1,059 (25.0%)	411 (6.9%)	411 (6.9%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)	3,142 (17.6%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
≥75 years	1,307 (39.4%)	1,307 (39.4%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	719 (16.5%)	1,283 (30.2%)	1,283 (30.2%)	121 (2.0%)	121 (2.0%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)	3,430 (19.2%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Sex, n (%)																	Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																																																																																																																																				
Male	1,417 (42.7%)	1,417 (42.7%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,327 (53.4%)	2,046 (48.7%)	2,046 (48.7%)	3,461 (58.1%)	3,461 (58.1%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)	9,279 (51.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Female	1,901 (57.3%)	1,901 (57.3%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,029 (46.6%)	2,199 (51.3%)	2,199 (51.3%)	2,499 (41.9%)	2,499 (41.9%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)	8,599 (48.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
US Geographic Region, n (%)																	East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)	Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																																																																																																																																																																																																								
East	72 (2.2%)	72 (2.2%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	724 (16.6%)	402 (9.5%)	402 (9.5%)	1,080 (18.1%)	1,080 (18.1%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)	2,278 (12.7%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Midwest	693 (22.2%)	693 (22.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	2,097 (48.2%)	1,175 (27.3%)	1,175 (27.3%)	1,491 (25.9%)	1,491 (25.9%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)	5,347 (30.0%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
South	2,065 (66.0%)	2,065 (66.0%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	2,065 (47.5%)	1,856 (42.8%)	1,856 (42.8%)	2,126 (36.5%)	2,126 (36.5%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)	7,372 (41.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
West	265 (8.0%)	265 (8.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	480 (11.0%)	856 (20.2%)	856 (20.2%)	588 (10.3%)	588 (10.3%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)	2,189 (12.2%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Other	—	—	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	15 (0.3%)	—	—	—	—	15 (0.1%)	15 (0.1%)	15 (0.1%)	15 (0.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Missing	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Comorbidity Profile																	Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															
Deyo-Charlson Comorbidity Index, mean (SD)	2.0 (2.1)	2.1 (2.1)	0.7 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	0.6 (1.2)	1.3 (1.8)	1.3 (1.8)	0.6 (1.2)	0.6 (1.2)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)	1.0 (1.7)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Comorbidities, n (%)																	Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)	Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)	Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)	Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
Acquired immunodeficiency syndrome (AIDS)	11 (0.4%)	11 (0.4%)	10 (0.2%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	11 (0.3%)	19 (0.4%)	19 (0.4%)	27 (0.5%)	26 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)	64 (0.4%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Alcohol abuse	148 (4.5%)	148 (4.5%)	87 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	86 (2.0%)	106 (2.4%)	106 (2.4%)	205 (3.4%)	205 (3.4%)	591 (3.3%)	591 (3.3%)	591 (3.3%)	591 (3.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Anemia	811 (24.4%)	811 (24.4%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	795 (18.2%)	701 (16.5%)	701 (16.5%)	686 (11.5%)	686 (11.5%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)	2,562 (14.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Bleeding	66 (2.0%)	67 (2.1%)	17 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	16 (0.4%)	65 (1.5%)	65 (1.5%)	81 (1.4%)	77 (1.3%)	261 (1.5%)	261 (1.5%)	261 (1.5%)	261 (1.5%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Central venous catheter	152 (4.6%)	137 (4.1%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	99 (2.3%)	181 (4.2%)	181 (4.2%)	255 (4.3%)	229 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)	689 (3.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Cerebrovascular disease (stroke/TIA)	406 (12.4%)	406 (12.4%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	276 (6.3%)	317 (7.3%)	317 (7.3%)	323 (5.5%)	323 (5.5%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)	1,242 (6.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Chronic obstructive pulmonary disease (COPD)	876 (26.4%)	876 (26.4%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	888 (20.0%)	598 (13.8%)	598 (13.8%)	398 (6.7%)	398 (6.7%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)	2,155 (12.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Coagulopathy	38 (1.1%)	49 (1.5%)	38 (0.9%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	30 (0.7%)	56 (1.3%)	56 (1.3%)	51 (0.9%)	51 (0.9%)	221 (1.2%)	221 (1.2%)	221 (1.2%)	221 (1.2%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Congestive heart failure	1,127 (34.0%)	1,127 (34.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	1,114 (25.0%)	924 (21.2%)	924 (21.2%)	874 (14.7%)	874 (14.7%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)	3,466 (19.4%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Ischemic heart/coronary artery disease	217 (7.1%)	184 (5.5%)	541 (12.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	441 (10.2%)	152 (3.5%)	152 (3.5%)	25 (0.4%)	21 (0.4%)	508 (2.8%)	425 (2.4%)	508 (2.8%)	425 (2.4%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Dementia	1,269 (39.4%)	1,269 (39.4%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	942 (21.6%)	1,100 (25.0%)	1,100 (25.0%)	1,040 (17.6%)	1,040 (17.6%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)	4,342 (24.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Diabetes	708 (22.1%)	708 (22.1%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	1,113 (25.3%)	978 (22.5%)	978 (22.5%)	1,031 (17.8%)	1,031 (17.8%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)	3,271 (18.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Disability	170 (5.1%)	170 (5.1%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	436 (10.0%)	323 (7.4%)	323 (7.4%)	371 (6.4%)	371 (6.4%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)	1,669 (9.3%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Fractures involving the lower extremities	76 (2.3%)	76 (2.3%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	217 (5.0%)	44 (1.0%)	44 (1.0%)	43 (0.8%)	43 (0.8%)	191 (1.1%)	191 (1.1%)	191 (1.1%)	191 (1.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Hemiplegia or paraplegia	2,150 (64.8%)	2,150 (64.8%)	1,747 (40.1%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	1,668 (38.3%)	2,120 (50.0%)	2,120 (50.0%)	1,907 (32.0%)	1,907 (32.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)	7,875 (44.0%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Hypertension	2,680 (80.8%)	2,680 (80.8%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,648 (79.6%)	2,499 (58.9%)	2,499 (58.9%)	2,054 (34.3%)	2,054 (34.3%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)	9,799 (54.8%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Hypertension inflammatory bowel syndrome	38 (1.1%)	35 (1.1%)	32 (0.7%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	37 (0.8%)	29 (0.7%)	29 (0.7%)	80 (1.3%)	94 (1.6%)	179 (1.0%)	190 (1.1%)	190 (1.1%)	190 (1.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Liver disease	235 (7.1%)	246 (7.4%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	154 (3.5%)	267 (6.3%)	267 (6.3%)	361 (6.1%)	361 (6.1%)	998 (5.6%)	1,031 (5.8%)	1,031 (5.8%)	1,031 (5.8%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Malignancy (excluding non-melanoma skin cancer)	50 (1.5%)	46 (1.4%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	21 (0.5%)	62 (1.4%)	62 (1.4%)	216 (3.7%)	216 (3.7%)	200 (1.1%)	200 (1.1%)	200 (1.1%)	200 (1.1%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Obesity	859 (25.9%)	843 (25.4%)	565 (13.0%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	580 (13.3%)	859 (20.2%)	859 (20.2%)	1,267 (21.3%)	1,267 (21.3%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)	3,549 (19.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
Peptic ulcer disease	52 (1.6%)	46 (1.4%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	39 (0.9%)	41 (0.7%)	41 (0.7%)	160 (0.9%)	154 (0.9%)	154 (0.9%)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						



**Online Supplement -- Table 3.** Use of index therapy among matched patients receiving apixaban and warfarin as outpatient therapy for VTE, overall and within study database, by index drug\*

	Humana		MarketScan		Optum		PharMetrics		Total Population	
	Apixaban (n=3,318)	Warfarin (n=3,318)	Apixaban (n=4,356)	Warfarin (n=4,356)	Apixaban (n=4,243)	Warfarin (n=4,243)	Apixaban (n=5,961)	Warfarin (n=5,961)	Apixaban (n=17,878)	Warfarin (n=17,878)
<b>Index Therapy</b>										
Number of prescriptions, mean (SD)	3.5 (2.3)	4.7 (4.1)	5.3 (4.2)	5.8 (4.7)	3.6 (2.2)	5.0 (4.7)	4.1 (2.1)	4.8 (3.1)	4.2 (2.9)	5.1 (4.2)
Number of therapy days, mean (SD)	109.2 (59.0)	134.9 (56.8)	119.6 (62.4)	127.2 (60.9)	112.9 (68.0)	151.9 (99.3)	120.0 (55.2)	131.3 (57.8)	116.2 (61.0)	135.8 (71.0)
Dose of index therapy, n (%)										
<b>First prescription</b>										
Apixaban	308 (9.3)	---	300 (6.9)	---	379 (8.9)	---	292 (4.9)	---	1,279 (7.2)	---
5 mg	3,010 (90.7)	---	4,056 (93.1)	---	3,864 (91.1)	---	5,669 (95.1)	---	16,599 (92.8)	---
<b>Second &amp; subsequent prescriptions</b>										
Apixaban	731 (22.0)	---	860 (19.7)	---	923 (21.8)	---	775 (13.0)	---	3,289 (18.4)	---
None	283 (8.5)	---	287 (6.6)	---	374 (8.8)	---	332 (5.6)	---	1,276 (7.1)	---
2.5 mg	2,359 (71.1)	---	3,284 (75.4)	---	3,045 (71.8)	---	4,980 (83.5)	---	13,668 (76.5)	---
5 mg										
<b>Switch from index therapy to another OAC, n (%)</b>										
Apixaban	0 (0.0)	126 (3.8)	0 (0.0)	165 (3.8)	0 (0.0)	160 (3.8)	0 (0.0)	255 (4.3)	0 (0.0)	706 (3.9)
Dabigatran	0 (0.0)	2 (0.1)	1 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	2 (0.0)
Edoxaban	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Rivaroxaban	5 (0.2)	2 (0.1)	6 (0.1)	4 (0.1)	4 (0.1)	3 (0.1)	0 (0.0)	0 (0.0)	15 (0.1)	9 (0.1)
Warfarin	87 (2.6)	0 (0.0)	83 (1.9)	0 (0.0)	110 (2.6)	0 (0.0)	152 (2.5)	0 (0.0)	432 (2.4)	0 (0.0)
<b>Use of PAC, n (%)</b>										
<b>Between index encounter and initiation of index therapy</b>										
Unfractionated heparin	1 (0.0)	2 (0.1)	1 (0.0)	3 (0.1)	0 (0.0)	3 (0.1)	0 (0.0)	0 (0.0)	2 (0.0)	8 (0.0)
Low molecular weight heparin										
Dalteparin	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	2 (0.0)	0 (0.0)	3 (0.0)
Enoxaparin	40 (1.2)	1,201 (36.2)	84 (1.9)	2,463 (56.5)	105 (2.5)	2,644 (62.3)	147 (2.5)	4,179 (70.1)	376 (2.1)	10,487 (58.7)
Tinzaparin	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fondaparinux	0 (0.0)	8 (0.2)	1 (0.0)	25 (0.6)	2 (0.0)	14 (0.3)	2 (0.0)	37 (0.6)	5 (0.0)	84 (0.5)
<b>Subsequently</b>										
Unfractionated heparin	8 (0.2)	10 (0.3)	0 (0.0)	6 (0.1)	2 (0.0)	9 (0.2)	0 (0.0)	0 (0.0)	10 (0.1)	25 (0.1)
Low molecular weight heparin										
Dalteparin	1 (0.0)	1 (0.0)	1 (0.0)	1 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	3 (0.1)	2 (0.0)	6 (0.0)
Enoxaparin	77 (2.3)	1,360 (41.0)	118 (2.7)	2,620 (60.1)	120 (2.8)	2,729 (64.3)	233 (3.9)	4,353 (73.0)	548 (3.1)	11,062 (61.9)
Tinzaparin	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Fondaparinux	2 (0.1)	12 (0.4)	0 (0.0)	37 (0.8)	5 (0.1)	22 (0.5)	10 (0.2)	51 (0.9)	17 (0.1)	122 (0.7)
Days of follow-up, mean (SD)	129.4 (61.3)	145.8 (55.0)	124.5 (63.2)	135.4 (60.9)	127.5 (61.4)	143.6 (55.9)	174.5 (22.9)	173.3 (28.1)	142.8 (56.9)	151.9 (52.1)

OAC: Oral anticoagulant; PAC: Parenteral anticoagulant

\*Use during 6-month follow-up period

**Online Supplement -- Table 4a.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- matched-samples analysis

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Major Bleeding Event							
All							
Apixaban	17,878	295	1.7%	4.2	0.75	0.64 - 0.87	<0.001
Warfarin	17,878	412	2.3%	5.5	--	--	--
Gastrointestinal							
Apixaban	17,878	111	0.6%	1.6	0.72	0.57 - 0.92	0.009
Warfarin	17,878	160	0.9%	2.2	--	--	--
Intracranial							
Apixaban	17,878	24	0.1%	0.3	0.97	0.56 - 1.69	0.920
Warfarin	17,878	26	0.1%	0.3	--	--	--
Other							
Apixaban	17,878	160	0.9%	2.3	0.74	0.60 - 0.90	0.003
Warfarin	17,878	226	1.3%	3.0	--	--	--
CRNM Bleeding Event							
All							
Apixaban	17,878	1,257	7.0%	18.0	0.77	0.71 - 0.83	<0.001
Warfarin	17,878	1,688	9.4%	22.7	--	--	--
Gastrointestinal							
Apixaban	17,878	385	2.2%	5.5	0.88	0.76 - 1.00	0.053
Warfarin	17,878	460	2.6%	6.2	--	--	--
Other							
Apixaban	17,878	874	4.9%	12.5	0.73	0.67 - 0.79	<0.001
Warfarin	17,878	1,238	6.9%	16.7	--	--	--
<b>Humana</b>							
Major Bleeding Event							
All							
Apixaban	3,318	99	3.0%	8.4	0.77	0.60 - 1.00	0.049
Warfarin	3,318	140	4.2%	10.6	--	--	--
Gastrointestinal							
Apixaban	3,318	43	1.3%	3.7	0.74	0.50 - 1.09	0.123
Warfarin	3,318	64	1.9%	4.8	--	--	--
Intracranial							
Apixaban	3,318	6	0.2%	0.5	0.96	0.32 - 2.85	0.935
Warfarin	3,318	7	0.2%	0.5	--	--	--
Other							
Apixaban	3,318	50	1.5%	4.3	0.79	0.55 - 1.14	0.207
Warfarin	3,318	69	2.1%	5.2	--	--	--
CRNM Bleeding Event							
All							
Apixaban	3,318	233	7.0%	19.8	0.79	0.67 - 0.94	0.007
Warfarin	3,318	316	9.5%	23.9	--	--	--
Gastrointestinal							
Apixaban	3,318	77	2.3%	6.5	0.76	0.57 - 1.01	0.062
Warfarin	3,318	110	3.3%	8.3	--	--	--
Other							
Apixaban	3,318	156	4.7%	13.3	0.81	0.66 - 0.99	0.042
Warfarin	3,318	209	6.3%	15.8	--	--	--

**Online Supplement -- Table 4a.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- matched-samples analysis

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>MarketScan</b>							
Major Bleeding Event							
All							
Apixaban	4,356	45	1.0%	3.0	0.94	0.63 - 1.40	0.760
Warfarin	4,356	51	1.2%	3.2	--	--	--
Gastrointestinal							
Apixaban	4,356	19	0.4%	1.3	1.20	0.62 - 2.30	0.590
Warfarin	4,356	17	0.4%	1.1	--	--	--
Intracranial							
Apixaban	4,356	3	0.1%	0.2	0.65	0.15 - 2.70	0.549
Warfarin	4,356	5	0.1%	0.3	--	--	--
Other							
Apixaban	4,356	23	0.5%	1.5	0.84	0.49 - 1.45	0.534
Warfarin	4,356	29	0.7%	1.8	--	--	--
CRNM Bleeding Event							
All							
Apixaban	4,356	310	7.1%	20.9	0.76	0.66 - 0.88	<0.001
Warfarin	4,356	424	9.7%	26.3	--	--	--
Gastrointestinal							
Apixaban	4,356	96	2.2%	6.5	0.93	0.71 - 1.23	0.617
Warfarin	4,356	109	2.5%	6.8	--	--	--
Other							
Apixaban	4,356	214	4.9%	14.4	0.71	0.59 - 0.84	<0.001
Warfarin	4,356	317	7.3%	19.6	--	--	--
<b>Optum</b>							
Major Bleeding Event							
All							
Apixaban	4,243	92	2.2%	6.2	0.80	0.61 - 1.05	0.102
Warfarin	4,243	124	2.9%	7.4	--	--	--
Gastrointestinal							
Apixaban	4,243	35	0.8%	2.4	0.71	0.47 - 1.10	0.124
Warfarin	4,243	53	1.2%	3.2	--	--	--
Intracranial							
Apixaban	4,243	7	0.2%	0.5	1.30	0.44 - 3.88	0.636
Warfarin	4,243	6	0.1%	0.4	--	--	--
Other							
Apixaban	4,243	50	1.2%	3.4	0.83	0.57 - 1.19	0.308
Warfarin	4,243	65	1.5%	3.9	--	--	--
CRNM Bleeding Event							
All							
Apixaban	4,243	264	6.2%	17.8	0.80	0.68 - 0.94	0.005
Warfarin	4,243	358	8.4%	21.5	--	--	--
Gastrointestinal							
Apixaban	4,243	91	2.1%	6.1	0.97	0.73 - 1.29	0.838
Warfarin	4,243	103	2.4%	6.2	--	--	--
Other							
Apixaban	4,243	174	4.1%	11.7	0.73	0.61 - 0.89	0.002
Warfarin	4,243	256	6.0%	15.3	--	--	--

**Online Supplement -- Table 4a.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- matched-samples analysis

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>PharMetrics</b>							
Major Bleeding Event							
All							
Apixaban	5,961	59	1.0%	2.1	0.60	0.44 - 0.83	0.002
Warfarin	5,961	97	1.6%	3.4	--	--	--
Gastrointestinal							
Apixaban	5,961	14	0.2%	0.5	0.53	0.28 - 1.02	0.059
Warfarin	5,961	26	0.4%	0.9	--	--	--
Intracranial							
Apixaban	5,961	8	0.1%	0.3	0.99	0.37 - 2.64	0.987
Warfarin	5,961	8	0.1%	0.3	--	--	--
Other							
Apixaban	5,961	37	0.6%	1.3	0.58	0.39 - 0.87	0.009
Warfarin	5,961	63	1.1%	2.2	--	--	--
CRNM Bleeding Event							
All							
Apixaban	5,961	450	7.5%	15.8	0.75	0.66 - 0.84	<0.001
Warfarin	5,961	590	9.9%	20.9	--	--	--
Gastrointestinal							
Apixaban	5,961	121	2.0%	4.2	0.87	0.68 - 1.11	0.267
Warfarin	5,961	138	2.3%	4.9	--	--	--
Other							
Apixaban	5,961	330	5.5%	11.6	0.71	0.62 - 0.82	<0.001
Warfarin	5,961	456	7.6%	16.1	--	--	--

CRNM: clinically relevant non-major; VTE: venous thromboembolism



**Online Supplement -- Table 4b.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with multivariable Cox proportional hazards models

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Major Bleeding Event							
All							
Apixaban	20,561	320	1.6%	4.0	0.71	0.62 - 0.81	<0.001
Warfarin	35,080	953	2.7%	6.6	--	--	--
Gastrointestinal							
Apixaban	20,561	118	0.6%	1.5	0.72	0.58 - 0.90	0.004
Warfarin	35,080	337	1.0%	2.3	--	--	--
Intracranial							
Apixaban	20,561	28	0.1%	0.3	0.71	0.46 - 1.10	0.125
Warfarin	35,080	85	0.2%	0.6	--	--	--
Other							
Apixaban	20,561	174	0.8%	2.2	0.70	0.59 - 0.84	<0.001
Warfarin	35,080	532	1.5%	3.7	--	--	--
CRNM Bleeding Event							
All							
Apixaban	20,561	1,452	7.1%	18.1	0.77	0.72 - 0.82	<0.001
Warfarin	35,080	3,354	9.6%	23.2	--	--	--
Gastrointestinal							
Apixaban	20,561	440	2.1%	5.5	0.90	0.80 - 1.01	0.086
Warfarin	35,080	920	2.6%	6.4	--	--	--
Other							
Apixaban	20,561	1,014	4.9%	12.6	0.73	0.68 - 0.79	<0.001
Warfarin	35,080	2,452	7.0%	17.0	--	--	--
<b>Humana</b>							
Major Bleeding Event							
All							
Apixaban	3,719	106	2.9%	8.1	0.74	0.59 - 0.93	0.010
Warfarin	5,949	273	4.6%	11.6	--	--	--
Gastrointestinal							
Apixaban	3,719	46	1.2%	3.5	0.76	0.54 - 1.08	0.124
Warfarin	5,949	111	1.9%	4.7	--	--	--
Intracranial							
Apixaban	3,719	7	0.2%	0.5	0.61	0.26 - 1.44	0.262
Warfarin	5,949	21	0.4%	0.9	--	--	--
Other							
Apixaban	3,719	53	1.4%	4.0	0.70	0.51 - 0.96	0.029
Warfarin	5,949	141	2.4%	6.0	--	--	--
CRNM Bleeding Event							
All							
Apixaban	3,719	261	7.0%	19.9	0.80	0.69 - 0.92	0.002
Warfarin	5,949	562	9.4%	23.8	--	--	--
Gastrointestinal							
Apixaban	3,719	87	2.3%	6.6	0.86	0.67 - 1.11	0.253
Warfarin	5,949	178	3.0%	7.5	--	--	--
Other							
Apixaban	3,719	174	4.7%	13.2	0.79	0.66 - 0.95	0.010
Warfarin	5,949	389	6.5%	16.5	--	--	--

**Online Supplement -- Table 4b.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with multivariable Cox proportional hazards models

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>MarketScan</b>							
Major Bleeding Event							
All							
Apixaban	5,748	55	1.0%	2.8	0.76	0.55 - 1.07	0.114
Warfarin	9,069	137	1.5%	4.1	--	--	--
Gastrointestinal							
Apixaban	5,748	22	0.4%	1.1	0.88	0.52 - 1.50	0.641
Warfarin	9,069	39	0.4%	1.2	--	--	--
Intracranial							
Apixaban	5,748	5	0.1%	0.3	0.52	0.19 - 1.43	0.205
Warfarin	9,069	15	0.2%	0.4	--	--	--
Other							
Apixaban	5,748	28	0.5%	1.4	0.72	0.46 - 1.14	0.161
Warfarin	9,069	83	0.9%	2.5	--	--	--
CRNM Bleeding Event							
All							
Apixaban	5,748	412	7.2%	20.8	0.77	0.69 - 0.87	<0.001
Warfarin	9,069	911	10.0%	27.1	--	--	--
Gastrointestinal							
Apixaban	5,748	120	2.1%	6.1	0.85	0.68 - 1.07	0.174
Warfarin	9,069	263	2.9%	7.8	--	--	--
Other							
Apixaban	5,748	292	5.1%	14.8	0.78	0.68 - 0.90	<0.001
Warfarin	9,069	653	7.2%	19.4	--	--	--
<b>Optum</b>							
Major Bleeding Event							
All							
Apixaban	4,419	93	2.1%	6.0	0.74	0.59 - 0.94	0.013
Warfarin	9,956	350	3.5%	8.9	--	--	--
Gastrointestinal							
Apixaban	4,419	35	0.8%	2.3	0.76	0.52 - 1.11	0.152
Warfarin	9,956	132	1.3%	3.4	--	--	--
Intracranial							
Apixaban	4,419	7	0.2%	0.5	0.60	0.27 - 1.37	0.229
Warfarin	9,956	32	0.3%	0.8	--	--	--
Other							
Apixaban	4,419	51	1.2%	3.3	0.76	0.55 - 1.03	0.079
Warfarin	9,956	187	1.9%	4.7	--	--	--
CRNM Bleeding Event							
All							
Apixaban	4,419	284	6.4%	18.4	0.81	0.70 - 0.92	0.002
Warfarin	9,956	839	8.4%	21.3	--	--	--
Gastrointestinal							
Apixaban	4,419	98	2.2%	6.4	1.11	0.88 - 1.41	0.386
Warfarin	9,956	229	2.3%	5.8	--	--	--
Other							
Apixaban	4,419	187	4.2%	12.1	0.71	0.60 - 0.84	<0.001
Warfarin	9,956	613	6.2%	15.6	--	--	--

**Online Supplement -- Table 4b.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with multivariable Cox proportional hazards models

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>PharMetrics</b>							
Major Bleeding Event							
All							
Apixaban	6,675	66	1.0%	2.1	0.64	0.48 - 0.85	0.002
Warfarin	10,106	193	1.9%	4.0	--	--	--
Gastrointestinal							
Apixaban	6,675	15	0.2%	0.5	0.54	0.30 - 0.97	0.038
Warfarin	10,106	55	0.5%	1.1	--	--	--
Intracranial							
Apixaban	6,675	9	0.1%	0.3	1.06	0.46 - 2.41	0.897
Warfarin	10,106	17	0.2%	0.4	--	--	--
Other							
Apixaban	6,675	42	0.6%	1.3	0.63	0.44 - 0.91	0.013
Warfarin	10,106	121	1.2%	2.5	--	--	--
CRNM Bleeding Event							
All							
Apixaban	6,675	495	7.4%	15.5	0.73	0.65 - 0.81	<0.001
Warfarin	10,106	1,042	10.3%	21.7	--	--	--
Gastrointestinal							
Apixaban	6,675	135	2.0%	4.2	0.88	0.71 - 1.09	0.226
Warfarin	10,106	250	2.5%	5.2	--	--	--
Other							
Apixaban	6,675	361	5.4%	11.3	0.69	0.61 - 0.79	<0.001
Warfarin	10,106	797	7.9%	16.6	--	--	--

CRNM: clinically relevant non-major; VTE: venous thromboembolism

**Online Supplement -- Table 4c.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with IPTW-ATE

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Major Bleeding Event							
All							
Apixaban	20,561	320	1.6%	4.0	0.71	0.63 - 0.80	<0.001
Warfarin	35,080	953	2.7%	6.6	--	--	--
Gastrointestinal							
Apixaban	20,561	118	0.6%	1.5	0.75	0.61 - 0.91	0.004
Warfarin	35,080	337	1.0%	2.3	--	--	--
Intracranial							
Apixaban	20,561	28	0.1%	0.3	0.73	0.48 - 1.09	0.121
Warfarin	35,080	85	0.2%	0.6	--	--	--
Other							
Apixaban	20,561	174	0.8%	2.2	0.68	0.58 - 0.81	<0.001
Warfarin	35,080	532	1.5%	3.7	--	--	--
CRNM Bleeding Event							
All							
Apixaban	20,561	1,452	7.1%	18.1	0.76	0.71 - 0.81	<0.001
Warfarin	35,080	3,354	9.6%	23.2	--	--	--
Gastrointestinal							
Apixaban	20,561	440	2.1%	5.5	0.90	0.80 - 1.00	0.058
Warfarin	35,080	920	2.6%	6.4	--	--	--
Other							
Apixaban	20,561	1,014	4.9%	12.6	0.71	0.66 - 0.76	<0.001
Warfarin	35,080	2,452	7.0%	17.0	--	--	--
<b>Humana</b>							
Major Bleeding Event							
All							
Apixaban	3,719	106	2.9%	8.1	0.77	0.62 - 0.96	0.021
Warfarin	5,949	273	4.6%	11.6	--	--	--
Gastrointestinal							
Apixaban	3,719	46	1.2%	3.5	0.84	0.60 - 1.16	0.292
Warfarin	5,949	111	1.9%	4.7	--	--	--
Intracranial							
Apixaban	3,719	7	0.2%	0.5	0.76	0.33 - 1.71	0.500
Warfarin	5,949	21	0.4%	0.9	--	--	--
Other							
Apixaban	3,719	53	1.4%	4.0	0.73	0.53 - 1.00	0.047
Warfarin	5,949	141	2.4%	6.0	--	--	--
CRNM Bleeding Event							
All							
Apixaban	3,719	261	7.0%	19.9	0.80	0.69 - 0.92	0.003
Warfarin	5,949	562	9.4%	23.8	--	--	--
Gastrointestinal							
Apixaban	3,719	87	2.3%	6.6	0.80	0.62 - 1.04	0.092
Warfarin	5,949	178	3.0%	7.5	--	--	--
Other							
Apixaban	3,719	174	4.7%	13.2	0.79	0.66 - 0.95	0.011
Warfarin	5,949	389	6.5%	16.5	--	--	--

**Online Supplement -- Table 4c.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with IPTW-ATE

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>MarketScan</b>							
Major Bleeding Event							
All							
Apixaban	5,748	55	1.0%	2.8	0.78	0.58 - 1.06	0.111
Warfarin	9,069	137	1.5%	4.1	--	--	--
Gastrointestinal							
Apixaban	5,748	22	0.4%	1.1	0.97	0.59 - 1.60	0.896
Warfarin	9,069	39	0.4%	1.2	--	--	--
Intracranial							
Apixaban	5,748	5	0.1%	0.3	0.61	0.23 - 1.62	0.321
Warfarin	9,069	15	0.2%	0.4	--	--	--
Other							
Apixaban	5,748	28	0.5%	1.4	0.71	0.47 - 1.08	0.112
Warfarin	9,069	83	0.9%	2.5	--	--	--
CRNM Bleeding Event							
All							
Apixaban	5,748	412	7.2%	20.8	0.77	0.69 - 0.87	<0.001
Warfarin	9,069	911	10.0%	27.1	--	--	--
Gastrointestinal							
Apixaban	5,748	120	2.1%	6.1	0.84	0.68 - 1.04	0.114
Warfarin	9,069	263	2.9%	7.8	--	--	--
Other							
Apixaban	5,748	292	5.1%	14.8	0.75	0.65 - 0.86	<0.001
Warfarin	9,069	653	7.2%	19.4	--	--	--
<b>Optum</b>							
Major Bleeding Event							
All							
Apixaban	4,419	93	2.1%	6.0	0.73	0.58 - 0.91	0.005
Warfarin	9,956	350	3.5%	8.9	--	--	--
Gastrointestinal							
Apixaban	4,419	35	0.8%	2.3	0.70	0.49 - 1.01	0.058
Warfarin	9,956	132	1.3%	3.4	--	--	--
Intracranial							
Apixaban	4,419	7	0.2%	0.5	0.59	0.26 - 1.32	0.198
Warfarin	9,956	32	0.3%	0.8	--	--	--
Other							
Apixaban	4,419	51	1.2%	3.3	0.77	0.57 - 1.03	0.078
Warfarin	9,956	187	1.9%	4.7	--	--	--
CRNM Bleeding Event							
All							
Apixaban	4,419	284	6.4%	18.4	0.83	0.72 - 0.94	0.005
Warfarin	9,956	839	8.4%	21.3	--	--	--
Gastrointestinal							
Apixaban	4,419	98	2.2%	6.4	1.14	0.90 - 1.43	0.278
Warfarin	9,956	229	2.3%	5.8	--	--	--
Other							
Apixaban	4,419	187	4.2%	12.1	0.72	0.61 - 0.84	<0.001
Warfarin	9,956	613	6.2%	15.6	--	--	--

**Online Supplement -- Table 4c.** Risks and hazard ratios for bleeding events among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with IPTW-ATE

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>PharMetrics</b>							
Major Bleeding Event							
All							
Apixaban	6,675	66	1.0%	2.1	0.65	0.50 - 0.84	0.001
Warfarin	10,106	193	1.9%	4.0	--	--	--
Gastrointestinal							
Apixaban	6,675	15	0.2%	0.5	0.58	0.34 - 0.98	0.043
Warfarin	10,106	55	0.5%	1.1	--	--	--
Intracranial							
Apixaban	6,675	9	0.1%	0.3	1.08	0.51 - 2.29	0.847
Warfarin	10,106	17	0.2%	0.4	--	--	--
Other							
Apixaban	6,675	42	0.6%	1.3	0.62	0.44 - 0.86	0.005
Warfarin	10,106	121	1.2%	2.5	--	--	--
CRNM Bleeding Event							
All							
Apixaban	6,675	495	7.4%	15.5	0.69	0.62 - 0.77	<0.001
Warfarin	10,106	1,042	10.3%	21.7	--	--	--
Gastrointestinal							
Apixaban	6,675	135	2.0%	4.2	0.86	0.70 - 1.06	0.171
Warfarin	10,106	250	2.5%	5.2	--	--	--
Other							
Apixaban	6,675	361	5.4%	11.3	0.64	0.57 - 0.73	<0.001
Warfarin	10,106	797	7.9%	16.6	--	--	--

CRNM: clinically relevant non-major; IPTW-ATE: inverse probability of treatment weighting-average treatment effect; VTE: venous thromboembolism

**Online Supplement -- Table 5a.** Risks and hazard ratios for recurrent VTE among patients receiving apixaban and warfarin as outpatient therapy for VTE -- matched-samples analysis

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Apixaban	17,878	403	2.3%	5.8	0.80	0.70 - 0.91	<0.001
Warfarin	17,878	521	2.9%	7.0	--	--	--
<b>Humana</b>							
Apixaban	3,318	86	2.6%	7.3	0.72	0.55 - 0.94	0.017
Warfarin	3,318	127	3.8%	9.6	--	--	--
<b>MarketScan</b>							
Apixaban	4,356	74	1.7%	5.0	0.90	0.66 - 1.23	0.506
Warfarin	4,356	87	2.0%	5.4	--	--	--
<b>Optum</b>							
Apixaban	4,243	92	2.2%	6.2	0.81	0.62 - 1.06	0.129
Warfarin	4,243	122	2.9%	7.3	--	--	--
<b>PharMetrics</b>							
Apixaban	5,961	151	2.5%	5.3	0.81	0.65 - 1.00	0.051
Warfarin	5,961	185	3.1%	6.5	--	--	--

VTE: venous thromboembolism

**Online Supplement -- Table 5b.** Risks and hazard ratios for recurrent VTE among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with multivariable Cox proportional hazards models

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Apixaban	20,561	440	2.1%	5.5	0.72	0.65 - 0.81	<0.001
Warfarin	35,080	1,218	3.5%	8.4	--	--	--
<b>Humana</b>							
Apixaban	3,719	92	2.5%	7.0	0.68	0.54 - 0.87	0.002
Warfarin	5,949	247	4.2%	10.5	--	--	--
<b>MarketScan</b>							
Apixaban	5,748	92	1.6%	4.7	0.90	0.69 - 1.16	0.408
Warfarin	9,069	203	2.2%	6.0	--	--	--
<b>Optum</b>							
Apixaban	4,419	95	2.1%	6.2	0.69	0.55 - 0.87	0.002
Warfarin	9,956	385	3.9%	9.8	--	--	--
<b>PharMetrics</b>							
Apixaban	6,675	161	2.4%	5.0	0.70	0.58 - 0.85	<0.001
Warfarin	10,106	383	3.8%	8.0	--	--	--

VTE: venous thromboembolism

**Online Supplement -- Table 5c.** Risks and hazard ratios for recurrent VTE among patients receiving apixaban and warfarin as outpatient therapy for VTE -- unmatched-samples analysis with IPTW-ATE

	No. Patients	No. Events	% Evented	Risk per 100 PY	HR	95% CI	p-value
<b>Total Population</b>							
Apixaban	20,561	440	2.1%	5.5	0.73	0.66 - 0.81	<0.001
Warfarin	35,080	1,218	3.5%	8.4	--	--	--
<b>Humana</b>							
Apixaban	3,719	92	2.5%	7.0	0.72	0.57 - 0.91	0.005
Warfarin	5,949	247	4.2%	10.5	--	--	--
<b>MarketScan</b>							
Apixaban	5,748	92	1.6%	4.7	0.88	0.69 - 1.12	0.298
Warfarin	9,069	203	2.2%	6.0	--	--	--
<b>Optum</b>							
Apixaban	4,419	95	2.1%	6.2	0.74	0.60 - 0.91	0.004
Warfarin	9,956	385	3.9%	9.8	--	--	--
<b>PharMetrics</b>							
Apixaban	6,675	161	2.4%	5.0	0.69	0.57 - 0.82	<0.001
Warfarin	10,106	383	3.8%	8.0	--	--	--

IPTW-ATE: inverse probability of treatment weighting-average treatment effect; VTE: venous thromboembolism